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Abstracts
Chapter 1: Macrocyclic peptides are important therapeutic candidates due to their improved
physicochemical properties in comparison to their linear counterparts. Here we detail a method
for a divergent macrocyclization of unprotected peptides by crosslinking two cysteine residues
with bis-palladium organometallic reagents. These synthetic intermediates are prepared in a
single step from commercially available aryl bis-halides. Two bioactive linear peptides with
cysteine residues at i, i + 4 and i, i + 7 positions, respectively, were cyclised to introduce a
diverse array of aryl and bi-aryl linkers. These two series of macrocyclic peptides displayed
similar linker-dependent lipophilicity, phospholipid affinity, and unique volume of distributions.
Additionally, one of the bioactive peptides showed target binding affinity that was
predominantly affected by the length of the linker. Collectively, this divergent strategy allowed
rapid and convenient access to various aryl linkers, enabling the systematic evaluation of the
effect of appending unit on the medicinal properties of macrocyclic peptides.
Chapter 2: We report the use of a sulfonated biarylphosphine ligand (sSPhos) to promote the
chemoselective modification of cysteine containing proteins and peptides with palladium
reagents in aqueous medium. The use of sSPhos allowed for the isolation of several air-stable
and water-soluble mono- and bis-palladium reagents, which were used in an improved protocol
for the rapid S-arylation of cysteines under benign and physiologically relevant conditions. The
cosolvent-free aqueous conditions were applied to the conjugation of a variety of biomolecules
with affinity tags, heterocycles, fluorophores, and functional handles. Additionally, bis-
palladium reagents were used to perform macrocyclization of peptides bearing two cysteine
residues.
Chapter 3: The synthesis of palladium oxidative addition complexes of unprotected peptides is
described. Incorporation of 4-halophenylalanine into a peptide during solid phase peptide
synthesis allows for subsequent oxidative addition at this position of the unprotected peptide
upon treatment with a palladium precursor and suitable ligand. The resulting palladium-peptide
complexes are solid, storable, water-soluble, and easily purified via high-performance liquid
chromatography. These complexes react rapidly with thiols at low micromolar concentrations in
an aqueous buffer, offering an efficient method for bioconjugation. Using this strategy, peptides
can be rapidly functionalized with small molecules to prepare modified aryl thioether side-
chains. Additionally, peptide-peptide and peptide-protein ligations are demonstrated under
dilute aqueous conditions.
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Introduction
The chemical modification of biomolecules, or bioconjugation,' is an important tool for
generating therapeutic conjugates, probing the structure or function of natural proteins, designing
novel constructs capable of performing unique functions, and diagnosing diseases.2 The
complexity and diversity of biomolecules presents many challenges for the design of new
bioconjugation reactions. In particular, the development of site-selective reactions to modify
biomolecules with high chemo- and regioselectivity is of utmost importance to ensure uniform
construction of bioconjugates. Additionally, transformations that occur under ambient, aqueous
conditions at low concentrations is highly valuable, as they avoid disrupting native structure and
function. 3
The tremendous advances in the application of transition metal catalysts in organic
chemistry are well chronicled.4 However, transition metal-mediated cross-coupling has only
recently emerged as an effective tool for the selective transformation of complex biomolecules.
These biomolecules, such as peptides and proteins, are structurally diverse, and they tolerate only
a narrow range of chemical environments that do not compromise the integrity of their structure
or function.6 Despite these challenges, recent innovations in organometallic chemistry have
inspired researchers to explore transition metal reagents for the selective modification of
biomolecules.5 Specifically, the development of transition metal-mediated transformations that
proceed in aqueous media, under mild conditions, exhibiting high selectivity, and excellent
functional group tolerance have been developed in the context of organic synthesis. These
qualities foreshadowed their usefulness for bioconjugation, for which exactly such benign
conditions and refined selectivity are often required.
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The cysteine amino acid residue, with its inherently low pKa (-8.3),7 low natural
abundance (0.5% - 2.3% abundance), and highly nucleophilic character,9 provides a useful
target for chemical modification. Cysteine-maleimide conjugation has seen widespread adoption
as a method of choice due to the rapid rate of this Michael addition reaction. However, this
reaction results in an unstable linkage prone to hydrolysis or retro-Michael addition (Figure 1).10
Several less widely-used methods for the modification of cysteine have also been introduced, yet
each retains significant drawbacks in either efficiency, ease of preparation, or linkage stability.7
Figure 1: Maleimide Linkage Instability. Maleimide conjugation to cysteine residues are prone
to hydrolysis or retro-Michael addition.
0
+ N-R
SH 1
0O0 0+ N-R JW N-R
SH S
OH
Recently, the combined research efforts of the Pentelute and Buchwald laboratories have
led to the development of palladium(II) oxidative addition complexes that are able to modify
cysteine residues of several classes of biomolecules under mild conditions (Figure 2). " Notably,
these cysteine arylation transformations have been shown to be highly chemoselective, rapid, and
tolerant of the functional groups present in proteins, peptides, and antibodies. Additionally, the
resulting C-S bonds demonstrated significantly increased linkage stability relative to cysteine-
maleimide linkages. Our findings toward the improvement of this methodology and the
discovery of new applications are described in this thesis.
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Figure 2: Previous work from Pentelute, Buchwald, and Coworkers on Cysteine
Arylation." (A) Synthesis of palladium(II) oxidative addition complexes and (B) S-arylation of
biomolecules under mild conditions.
A:
Me XMS RuPhos (1.1 equiv) 
_PM
Ru%-hos Cy NoIPr Me
1.1 equiv rt, 12 h, glovebox X
X = OTf, I,
Br, Cl (RuPhos)Pd(X)Tolyl
B:
Ar"!OH SH COOH 20 mM Tris,150 mM NaCl OH S' COOH
PCY-2- I - pH 7.51 1
Pr+H3N b / C(O)NH DMF: H20 H2N biomolecules: C(O)NH2
-.r 4 5:95
0OHN 0mn H2N NH
NH N NH then HS ^.CO2H H NHNH N::z/ NHN Jpalladium reagents biomolecules cysteine arylation
small molecules peptides rapid and chemoselectivebloconjugate handles proteins broad substrate scopedrugs antibodies stable products
One potential application of this newly discovered bioconjugation reaction is the
production of macrocyclic, or "stapled," peptides. Macrocyclic peptides are a remarkably varied
family of peptides found in a broad range of therapeutic applications due to their ability to
potentially inhibit protein-protein interactions,12 permeate through specific cells,13 resist
proteolytic degradation,' 4 and act as drugs themselves.' 4 Macrocyclic peptides can be produced
by forging one of several types of bonds across a peptide backbone, such as head-to-tail, head-to-
sidechain, sidechain-to-tail, and sidechain-to-sidechain linkages.1 5 Due to the interest in the
development of new therapeutic agents using these structures, several types of ring-forming
reactions have been discovered, including lactam formation,' 6 ring-closing metathesis, 7 disulfide
formation,' 8 and alkylation.1 9 A notable limitation of all of these strategies is the inability to
introduce structural diversity (e.g., incorporation of a variety of functional groups) in the linker
at a late stage of macrocyclic peptide synthesis. Chapter 1 of this thesis focuses on the
development of a divergent macrocyclisation strategy using bis-palladium oxidative addition
complexes capable of installing distinct aryl, biaryl, and biaryl ether elements into peptides
13
containing two cysteine residues. This method allowed us to evaluate the effects of cross-linkers
on important pharmaceutical properties such as lipophilicity, human serum albumin binding,
target affinity binding, and volume of distribution.2 0
As mentioned previously, the development of bioconjugation reactions that adhere to
biologically relevant conditions is of importance when seeking to modify sensitive
biomolecules. 3 Chapter 2 focuses on the use of a modified supporting ligand for the preparation
of the oxidative addition complexes that allows for the palladium-mediated cysteine arylation
reaction to proceed under ambient, aqueous conditions without diminished reactivity. 2' These
studies showcase an advantage of transition metal-mediated bioconjugation, namely, the ability
for palladium complexes to be structurally tailored to produce the desired selectivity and
reactivity.
Finally, Chapter 3 focuses on the development of a new class of palladium(II) oxidative
addition complexes. Through the introduction, during solid-phase peptide synthesis, of an
unnatural amino acid that contains an aryl halide, it is possible to form previously unreported
palladium-biomolecule type oxidative addition complexes. Subsequent reactions between these
complexes are possible with a variety of nucleophiles such as small molecules, peptides, and
proteins, resulting in the direct functionalization of biomolecules and effectively reversing the
reactivity of the previously described palladium-mediated S-arylation methods.
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Chapter 1. Divergent Unprotected Peptide Macrocyclization by Palladium-Mediated
Cysteine Arylation
16
1.1 - Introduction:
The selective inhibition of protein-protein interactions (PPIs) is a general tactic that
may lead to the development of therapeutics for targets once thought "undruggable."l One
approach to achieve this is the use of peptide inhibitors, which feature high potency,
selectivity, and often have low toxicity. Linear peptides, however, are readily degraded
by proteases, exhibit low cell-permeability, and often adopt disordered conformations that
affect their target binding affinity.5 Peptide macrocyclization has emerged as a
compelling strategy to overcome these issues.6-9 Compared to their linear counterparts,
macrocyclic peptides often display enhanced binding affinity, resistance to protease
degradation, and in certain cases, readily enter cells.4' 10 However, few systematic studies
of the pharmacokinetic and physicochemical properties (e.g. lipophilicity and
phospholipid affinity) have been reported.
Numerous synthetic tools for peptide macrocyclization have been developed in recent years.
One notable strategy is the crosslinking of two amino acid side chains. Classic techniques utilise
lysine and glutamic acid/aspartic acid residues for lactam formation." More recently, these
techniques have been augmented by protocols involving ring-closing metathesis, 2
cycloaddtions, 3"1 4 oxime formation,' 5 alkylation,16 thiol-ene reaction,17 arylation chemistry by
nucleophilic aromatic substitution (SNAr), 8" 9 and metal-mediated reactions.20 Many of these
macrocyclization protocols rely on unnatural amino acids requiring multistep synthesis to
diversify their structures. Few methods allow for modular tuning of the linker structure without
altering the amino acid sequences.21-24 Previous studies have indicated that the nature of the
linker strongly influence the stability, structure, binding affinity, and cell permeability of
macrocyclic peptides. 8 ,19,21 However, it is unclear how linkers influence the pharmacokinetic
17
Figure 1: S-arylation and macrocyclization of unprotected peptides. This work expanded the
Palladium-mediated S-arylation chemistry (A) to peptide macrocyclization (B), providing a
diverse array of aryl linkers with the capability to tune and manipulate the physiochemical
properties of the resulting macrocyclic peptides.
A. Palladium-mediated cysteine S-arylation
S H 0 1 % PCy2  O
H2N unr+ iPr Ar-1 H2N unprotected peptideNH2  NH22 9O~fl
B. Divergent unprotected peptide macrocyclization with bis-palladium reagents
L r/ L r-&
L = RuPhos ligand X 1 H2N-unprotected peptidefX = CI or Br HN 2
_Hrs& TunableHL HS L pharmacokinetic
H2N unprotected peptide H X X H2N unprotected peptide 0 pos philnity
NH2  NH 2 Phospholipid affinity2 NH2 HSA binding
Target binding
'AH2 unprotected peptide
NH 2
properties such as lipophilicity, phospholipid affinity, volume of distribution, and Human Serum
Albumin (HSA) binding profiles. It remains uncertain if these physicochemical properties can be
modulated, generally, based on linker design or if their impact is peptide sequence dependent.
Understanding the effect of linkers on these parameters will aid in assessing the "drug likeness"
of macrocyclic peptides and facilitate the development of future therapeutics.
Recently, we have described a palladium-mediated method for cysteine arylation (Fig.
1A), using biaryldialkylphosphine-based complexes of type LPd(Ar)(X) (X = Cl, Br, OTf; L =
ligand) as arylating reagents. Preliminary application to peptide macrocyclization was
demonstrated using a 4-4'-benzophenone-linked bis-palladium reagent along with a few others,
resulting in effective crosslinking of two cysteine residues at the i, i+4 positions of an
unprotected peptide.25 Here we report expanding this method to synthesis of aryl linkers of
18
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varying length, rigidity, and electronic properties (Fig. 1B) and a systematic study of the effect
of linkers on the lipophilicity, HSA binding, phospholipid affinity, and target binding affinity of
these macrocyclic peptides. In particular, a series of bis- palladium reagents were readily
prepared from commercially available aryl bis-halides. These air-stable palladium reagents were
used to macrocyclize two bioactive peptides: a peptide (NYAD-1) that binds the HIV-1 C-
terminal capsid protein (C-CA) with cysteine residues at the i, i+4 positions and a p53/MDM2
inhibitor analogue based on the p53 protein with cysteine residues at the i, i+ 7 positions.' ,26,27
These two model systems are employed in peptide macrocyclization studies and would let us
determine if the resulting physicochemical trends were dependent on peptide sequences or
crosslinking positions. The generality of this approach should allow for the further development
of therapeutic reagents that can be finely tuned to meet the challenges during the development of
peptide therapeutics.
1.2 - Results and Discussion:
To initiate our study, a series of bis-palladium complexes (OA-Y, Table 1) were synthesized
as macrocyclization reagents. 2-dicyclohexylphosphino-2',6'-diisopropoxybiphenyl (RuPhos)
was selected as the ligand for palladium, in combination with a series of aryl, biaryl, and biaryl
ether dihalides, eight oxidative addition complexes were synthesized (OA-A through OA-I).
These were chosen to probe the effects of linker length, rigidity, and degree of fluorination on
the physicochemical properties of the macrocyclized peptide.
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Table 1. One-step
in good yields.
X X
X = CI, Br
1 equiv
100 mM
synthesis of oxidative addition complexes as stapling reagents are synthesized
RuPhos
,d:: - TMS (2.2 equiv, 220 mM) PCy 2+ ' J OPr
TMS cyclohexane iPry r
2.2 equiv rt, 12 h /2 XA220 mM
[(RuPhos)Pd(X)] 2Ar
OA-A OA-B Me
X=Br
99%
OA-G
X=Br
93%
Me
X=CI
89%
OA-C F
X = Br
90%
OA-I
X=CI
86%
OA-D F
F
X=Br
85%
Reported isolated yields are an average of two runs after purification. Oxidative addition
complexes are air-stable and readily characterized by solution 'H, "P, and '9F NMR (where
applicable), elemental analysis, and FT-IR (See Experimental for characterization).
As shown in Table 1, the bis-palladium macrocyclization reagents were prepared in good
to excellent yields, regardless of the substitution pattern of the aryl dihalide. These oxidative
addition complexes could be stored under air at 4 *C for extended periods without loss of
reactivity, as demonstrated by similar reaction profiles of a freshly prepared sample and a sample
stored in a freezer at 4 "C for more than two years (see Experimental for details).
Using a combination of batch and rapid flow solid phase peptide synthesis (SPPS), 2 8
peptides P1 and P2 were synthesized on resin, cleaved, and later purified by reverse-phase
HPLC to afford the starting material for the subsequent macrocyclization reactions (see
Experimental for details). Peptide P1 is a variant of a known inhibitor of the HIV-1 C-terminal
capsid protein (C-CA) 27 and peptide P2 is a mutant of a peptide that disrupts p53/MDM2
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OA-E F3C
CF3
X = CI
83%
OA-J Me
X=CI
75%
interaction based on the p53 protein.' 0 Cysteine residues were placed at i, i+4 and i, i+7
positions for P1 and P2, respectively. As such, these two systems will allow us to probe whether
linkers will have the same effect when the peptide sequence and the position of the crosslinking
is varied.
Fine-tuning of the reaction conditions led to an optimised protocol for peptide
macroclisation (Fig. 2, top). Exposure of the purified peptides P1 and P2 to these conditions
afforded macroclyclisation products in good to excellent yields (70-99%, Fig. 2) as determined
by LC-MS analysis of the crude reaction mixtures (see Experimental for details). As shown by a
representative LC- MS trace, the crude reaction mixtures generally contained only desired
macrocyclic product along with a few by-products derived from the macrocyclization reagent
(see Experimental for full characterization of each purified macrocyclic peptide). Upon
completion of the reaction, the crude reaction mixture was treated with 3-thiopropionic acid,25 29
subjected to centrifugation, and the supernatant liquid was lyophilized and subsequently purified
by reverse-phase HPLC. ICP-MS analysis of the purified peptides showed that more than 99% of
palladium was removed using this purification protocol. Importantly, dimerization of two
peptides was not observed. Side reactions whereby two peptides form dimers are common
complications for two-component macrocyclization reactions, but were not found here.6 The
perfluorinated macrocyclic peptides P1-F, P2-F, P1-H, and P2-H (Table 3) were synthesized by
previously reported SNAr chemistry.' 8
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Figure 2. S-arylation and macrocyclization of unprotected peptides. This work expanded the
Palladium-mediated S-arylation chemistry (A) to peptide macrocyclization (B), providing a
diverse array of aryl linkers with the capability to tune and manipulate the physiochemical
properties of the resulting macrocyclic peptides.
SH HS P-y2
Q 91~~OPr PC2 ~ 0.1 M Tris (pH 7.5) -upoet
H2Nunprotected peptide H + PrO .. . H2N unprotected pept H)4
0. M NH2  I MeCN: H20 (1: 1) NH20.1 mM rt, 30 min P1-Y or P2-Y
P1: NH 2-ILTFCDLLCYYGKKK-C(O)NH 2  then HS CO2H
P2: NH 2-LTFCHYWAOLCS-C(O)NH 2  0.2 mMOA-Y
MeF
94% PI -) 9% (P-B)85% (P1-C) 70-13-3
85 12A e 84% (P32-B) I 92% (132-C)F 81%(3-)
Me
F3C I-E 99% (P2-G) 7%(P21-I) 99~ XL %(P2 -J)
90%(12-)\ 99%(1-G) 99 (1-i) r99% (1-J)
CF3
[M+3H 2H2+ Pd-species F
753.69 [M+2H] decomposition
Representative LC-MS 1130.02 Pdt by-products
spectrum of crude CF3
reaction mixture for P2-E 800 1000
SM
0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5
After purifying the conjugates, we sought to investigate how the linking units affect the
lipohilicity, human serum albumin (HSA) binding profiles, and if possible, the phospholipid
affinity and volume of distribution for these macrocyclic peptides.
Lipophilicity is a critical parameter for drug formulation and which determines whether a
compound will have the tendency to dissolve into lipid or aqueous environments.' 8 This is an
important consideration for pharmaceutical discovery and part of Lipinski's 'Rule of 5.'3' For
neutral small molecules, lipophilicity is often measured as Log P where P is the partitioning
coefficient between octanol and water. For compounds potentially exhibiting zwitterionic
character, a more appropriate measure is Log D where D is the distribution coefficient, which
measures the overall distribution of both ionised and neutral forms of the compound when the
aqueous phase is buffered to a particular pH. 0 We sought to determine whether this parameter
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could be manipulated for macrocyclic peptides by varying just the aryl linkers. Being able to
successfully modulate this parameter without disrupting other activity profiles could be a useful
tactic for peptide drug development.
Using known methods,3 ' retention time of the HPLC profiles of cyclised and linear
variants of peptides P1 and P2 were measured and correlated to octanol-water distribution in
solutions buffered to pH 7.4. Retention times, and mass spectrometric data were correlated to
literature values for the Log D of other compounds and then used to assign numerical values of
lipophilicity to these peptides.
Fig. 3A shows how these Log D7.4 values can be manipulated between 1.8 for uncyclised
P1-K to 2.7 for P1-C and P1-J. Interestingly, P1-G and P1-H exhibit the same Log D7.4 value
of 2.0, indicating that incorporation of fluorine substituents does not necessarily lead to increased
lipophilicity. Peptides P1-B and P1-E (methyl substituted and p-trifluoromethyl phenyl linkers),
however, do differ slightly with Log D7.4 values of 2.3 and 2.4, respectively.
To determine whether the measured lipophilicity depends on peptide sequence and crosslinking
positions, we also cyclised a variant of the P53/MDM2 inhibitor, P2, and measured lipophilicity
values using the same methods (Fig. 3B).
Notably, the cyclisation of peptide P2 significantly increased the lipophilicity values
from 0.6 for uncyclised P2-K to 2.9 for P2-J. The methylated diaryl ether cross linker again
yielded the highest Log D values for both peptides. However, the change in Log D does not
solely depend on the linker, rather a combination of linker and peptide. For instance, P1-C has
the same Log D as P1-J, but for P2-C the lipophilicity is intermediate. Another notable example
is for linker B, peptides P1-B and P2-B display contrasting lipophilicities.
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Figure 3. Lipophilicity measurements of two series of macrocyclic peptides show
dependency on relationship between linker structure and amino acid sequence. Log D at pH
7.4, a measurement of lipophilicity for amphiphillic compounds, as measured by dissolving
peptides in DMSO followed by rapid LC-UV-MS correlated to water/octanol partitioning for
each macrocyclic peptide. Lipophilicity shows dependence on both crosslinker and amino acid
composition.
A J SB ______Are -l0 Bs S
H2N ge-Thr-Ph.-Cys-Asp-Leu-Lou-Cys-Tyr-Tyr-GyLys H2N-Lu-Thr-Ph-Cy-His-Ty-rAa-Gin-LU
NH 2 NH 2
2.9
2.7 linear
2.5 0
2.3 NH2
2.1
(2R)d1.9-
1.7 -
1.5
1.3
1.1
0.9
0.7
P1-A P1-B P1-C P1-D P1-E P1-F P1-G P1-H P1-1 P1-J P1-K
Peptide
2.9
2.7
2.5
2.3
2.1
1.7
1.5 linear
1.3 0
1.1 NH2
0.7 - (2R)
0.5 -
P2-A P2-B P2-C P2-D P2-E P2-F P2-G P2-H P2-1 P2-J P2-K
Peptide
Another parameter governing therapeutic utility is human serum albumin (HSA) binding.
HSA, a prominent protein in plasma, is capable of binding many different classes of ligands.
This binding is partially responsible for the pharmacokinetic behaviour of many drugs and can
strongly influence their efficacy and delivery.3 2 By using a stationary phase comprising
immobilized HSA, the propensity of a molecule to bind to this protein can be determined by
HPLC methods. Although minor deviations in HSA binding were observed, all macrocyclized
P1 and P2 variants were found to exhibit high HSA binding percentage, regardless of the aryl
crosslinker (see Experimental for details).
Measurement of gradient HPLC retention times on immobilized artificial membrane
columns allows for phospholipid binding analysis (CHI IAM 7 .4 ). In conjunction with the
lipophilicity results, modelling of volume of distribution (VD) can be performed on the modified
peptides.34 VD relates administered doses of drugs to their distribution between tissues and
plasma in vivo. Knowledge of this parameter, along with clearance times, allows for the duration
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of drug exposure to be estimated, making VD another key pharmacokinetic parameter in the
development of new therapeutics.
Table 2: Phospholipid affinity and volume of distribution for the P2 peptides controlled by
linker structure. CHI IAM, chromatographic hydrophobicity index obtained on an immobilized
artificial membrane column were used along with HSA binding to calculate Log VD values.3 4
Peptide CHI lAM pH 7.4 Log VD
P2-A 47.3 0.46
P2-B 36.7 -0.26
P2-C 48.2 0.49
P2-D 46.1 0.35
P2-E 49.9 0.59
P2-F 49.2 0.59
P2-G 64.5 2.37
P2-H 59.2 1.54
P2-1 61.8 1.90
P2-J 70.0 3.42
P2-K 32.4 0.13
The results presented in Table 2 are for peptides based on the p53/MDM2 inhibitor P2.
Undesirable physicochemical properties can lead to a promiscuous profile and increased adverse
effects. For a given lipophilicity, basic compounds tend to be less selective.3 5 Phospholipid
affinity, a measure of this property, was therefore determined for the macrocyclized peptides.
Four P2 peptides P2-G-J demonstrate high phospholipid affinity and considerably higher
predicted volumes of distribution and would be expected to have a higher promiscuity index than
25
other P2 peptides. This is an example of when the HPLC biomimetic methodologies can offer a
perspective in structure activity relationships for pharmaceuticals. VD values could not be
obtained for the P1 variants due to the high levels of binding to the immobilized artificial
membrane column, which could be indicative of large tissue to plasma ratios in vivo.
Tuning the physiochemical properties without diminishing the activity of a peptide is
valuable for developing peptide therapeutics. We chose P1 variants to study how the linkers
affect the binding of these macrocyclic peptides to C-CA. Biotinylated Pt variants were prepared
for immobilization on the streptavidin biosensors and were sampled against serially diluted
concentrations of C-CA using BioLayer Interferometer (see Experimental for details). Two
control peptides with scrambled sequences, P4-A and P4-K, were also measured to ensure that
the observed binding events were not due to nonspecific binding of the aryl linkers (Table 3).
The linear control peptide (P1-K) showed an equilibrium dissociation constant (KD) of
5.5 0.6 pM in line with previous literature reports.27,36 All of the mono-aryl linkers with 1,4-
substitutions (P1-B, P1-D, P1-E, and P1-F) had KD comparable to the linear control. However,
variant P1-C with 1,3-substitution showed slightly lower binding affinity (KD 21.0 2.4 pM).
Moreover, macrocyclic peptides with the biphenyl and biaryl ether crosslinkers all showed little
to no binding affinity to C-CA. Taken together, these results indicated that the length of the
crosslinker mpact binding to the target. It is worth noting that, although differing greatly in their
lipophilicity (Fig. 3), the 1,4-substituted mono-aryl linkers (P1-B, P1-D, P1-E, and P1-F) did
not exhibit significant differences in binding affinity C-CA.
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Table 3. Target binding affinity for P1 macrocyclic peptides. Reported dissociation constants
(KD) for macrocyclic peptide variants of P1 and the scrambled P4 controls against the C-terminal
domain of HIV- 1 capsid protein (C-CA), as measured by BioLayer Interferometry.
Peptide Cross-linker KD (KM)
P1-A
Me
P1-B
Me
F
P1-C
F
P1-D
F
F 3C
P1-E I
CF 3
F F
P1-F
F F
P1-G
F F F F
P1-H
F F F F
P1-I 0
P1-J
P1-K
P4-A
P4-K
Me
2 x NH 2
2 x I NH 2
9.2t 0.4
9.7 t 0.4
21.0 t 2.4
9.5 t 0.5
12.0 t 0.8
12.0 t 0.6
61 t 35
>100
56t 21
>100
5.5 t 0.6
>100
>100
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1.3 - Conclusion:
We have shown that palladium-mediated S-arylation chemistry is a "shovel ready"
technology for rapid and straightforward divergent macrocyclization of peptides; linkers,
sequences, and crosslinking positions can be varied. Preparation of bis-palladium crosslinking
reagents is straightforward and one-step from commercially available aryl dihalides. The linker
had a significant affect on the physicochemical properties and in some cases the target binding
affinity was maintained.
The design and eventual use of macrocyclic peptides in the clinic is uncharted, especially
when compared to small molecules. Here we show by combining powerful chemistry, and
simple chromatographic techniques to measure the physicochemical properties of each variant
we could rank order peptides on basis of protein binding, lipohilicity, phospholipid affinity, and
predicted volume of distribution. These measurements may find application in medicinal
chemistry by providing a means to filter out peptides with undesirable physicochemical
characteristics such as high phospholipid affinity at an early stage within the drug discovery
process.
1.4 - Experimental:
General Reagent Information
1 -[Bis(dimethylamino)methylene]- 1 H-1,2,3-triazolo[4,5- b]pyridinium 3-oxid
hexafluorophosphate (HATU), D-Biotin, Fmoc-Rink amide linker, Fmoc-L- Gly-OH, Fmoc-L-
Leu-OH, Fmoc-L-Lys(Boc)-OH, Fmoc-L-Ala-OH, Fmoc-L-Cys(Trt)-OH, Fmoc-L-Gln(Trt)-
OH, Fmoc-L-Asn(Trt)-OH, Fmoc-L-Glu(OtBu)-OH, Fmoc-L-Arg(Pbf)-OH, Fmoc-L-Phe-OH,
Fmoc-L-Ser(tBu)-OH, Fmoc-L-Thr(tBu)-OH, Fmoc-L-Tyr(tBu)-OH, and Fmoc-L-His(Trt)-OH
were purchased from Chem-Impex International (Wood Dale, IL). Peptide synthesis-grade
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N,N-dimethylformamide (DMF), dichloromethane (CH 2Cl 2), diethyl ether, HPLC-grade
acetonitrile, and guanidine hydrochloride were obtained from VWR International (Philadelphia,
PA). Aryl halides and aryl trifluoromethanesulfonates were purchased from Aldrich Chemical
Co., Alfa Aesar, or Matrix Scientific and were used without additional purification. All
deuterated solvents were purchased from Cambridge Isotopes and used without further
purification. All other reagents were purchased from Sigma-Aldrich and used as received.
All reactions with peptides were set up on the bench top and carried out under ambient
conditions. For procedures carried out in the nitrogen-filled glovebox, the dry degassed THF was
obtained by passage through activated alumina columns followed by purging with argon.
Anhydrous pentane, cyclohexane, and acetonitrile were purchased from Aldrich Chemical
Company in Sureseal* bottles and were purged with argon before use.
All small-molecule organic and organometallic compounds were characterized by 'H, "C
NMR, and IR spectroscopy, as well as elemental analysis or high resolution mass spectrometry
(unless otherwise noted). 19F NMR spectroscopy was used for organometallic complexes
containing fluorine atoms. 3P NMR spectroscopy was used for characterization of palladium
complexes. Copies of the 'H, '3 C, "P, and 19F NMR spectra can be found at the end of the
Experimental Section. Nuclear Magnetic Resonance spectra were recorded on a Bruker 400 MHz
instrument and a Varian 300 MHz instrument. Unless otherwise stated, all 'H NMR experiments
are reported in 6 units, parts per million (ppm), and were measured relative to the signals of the
residual proton resonances CH2Cl 2 (5.32 ppm) or CH3CN (1.94 ppm) in the deuterated solvents.
All 13 C NMR spectra are measured decoupled from 'H nuclei and are reported in 6 units (ppm)
relative to CD2 Cl2 (54.00 ppm) or CD3CN (118.69 ppm), unless otherwise stated. All 3 'P NMR
spectra are measured decoupled from 'H nuclei and are reported relative to H3PO4 (0.00 ppm).
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19F NMR spectra are measured decoupled from 1H nuclei and are reported in ppm relative to
CFCl 3 (0.00 ppm) or a,a,a-trifluorotoluene (-63.72 ppm). All FT-IR spectra were recorded on a
Thermo Scientific - Nicolet iS5 spectrometer (iD5 ATR - diamond). Elemental analyses were
performed by Atlantic Microlabs Inc., Norcross, GA. Inductively Coupled Plasma Mass
Spectrometry (ICP-MS) was performed using an Agilent 7900.
LC-MS chromatograms and associated mass spectra were acquired using Agilent 6520
ESI-Q-TOF mass spectrometer. Solvent compositions used in the LC-MS are 0.1% formic acid
in H20 (solvent A) and 0.1% formic acid in acetonitrile (solvent B). The following LC-MS
method was used:
Method A LC conditions: Zorbax 300SB C3 column: 2.1 x 150 mm, 5 ptm, column temperature:
40 0C, gradient: 0-3 min 5% B, 3-8 min 5-95% B, 8-9 min 95% B, flow rate: 0.8 mL/min. MS
conditions: positive electrospray ionization (ESI) extended dynamic mode in mass range 300 -
3000 m/z, temperature of drying gas = 350 'C, flow rate of drying gas = 11 L/min, pressure of
nebulizer gas = 60 psi, the capillary, fragmentor, and octapole rf voltages were set at 4000, 175,
and 750, respectively.
Determination of Macrocyclization Yields
Data were processed using Agilent MassHunter software package. All reported yields
were determined by integrating total ion current (TIC) spectra. First, the peak areas for all
relevant peptide-containing species on the chromatogram were integrated using Agilent
MassHunter software package. Since no peptide-based side products were generated in the
experiments, the yields shown in Table 2 were determined as follows: %yield = Spr/Stotal where
Spr is the peak area of the product and Stotal is the peak area of combined peptide-containing
species (product and starting material).
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Synthesis of Oxidative Addition Complexes
Synthesis of [(1,5-COD)Pd(CH 2TMS)2]. A flame-dried Schlenk flask (100 mL), equipped with
a magnetic stir bar, was filled with argon and charged with (1,5-COD)PdCl 2 (3.15g, 11.05 mmol)
made according to literature reports.' The flask was put under vacuum and backfilled with argon
(the procedure was repeated 3 consecutive times). Diethyl ether (49.3 mL) was added via
syringe, the reaction was cooled to -40 'C (acetonitrile/dry ice bath) and TMSCH2MgCl (23.4
mL, 1.0 M) purchased from Sigma-Aldrich was added dropwise over 10-20 min. The reaction
mixture was stirred at -40 'C for 1 h and then at 0 'C (ice/water bath) for an additional 20 min.
Acetone (1.3 mL) was added at 0 'C, the reaction mixture was stirred for 5 min, after which time
the solvent was removed under vacuum using an external trap (the flask was kept at 0 C). The
flask was then opened to air, pentane (100 mL) was added and the crude material was filtered
through a pad of Celite into a new round-bottom flask (500 mL) at 0 'C. The filter cake was
washed with pentane (50 mL x 2). Pentane from the combined washes was removed with the aid
of a rotary evaporator at 0 'C (ice/water bath). The resulting white solid was dried under vacuum
for 2 h at 0 'C, and transferred into a 20 mL scintillation vial in the glovebox (3.00 g, 70%). The
'H and '3 C NMR spectra of the obtained material are identical to those reported in the literature.'
The title compound was stored in the glovebox at -20 'C.
General Procedure for the Synthesis of bis-Palladium Oxidative Addition Complexes.
RuPhos (2.2 equiv) -
X solvent PCY 2
"WMS r#L 4,rl
X XB 2.2 equiv XVO
=Cl, Br -Zi'T S[~O :-~ 2
1 equiv [(RuPhos)Pd(X)] 2Ar
In a nitrogen-filled glovebox, an oven-dried scintillation vial (10 mL), equipped with a
magnetic stir bar, was charged with RuPhos (2.2 equiv), Ar-X2 (1 equiv), and cyclohexane.
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Solid (1,5-COD)Pd(CH 2SiMe 3)2 (2.2 equiv) was added rapidly in one portion and the resulting
solution was stirred for 16 h at rt. After this time, pentane (3 mL) was added and the resulting
mixture was placed into a -20 'C freezer for 3 h. The vial was removed from the glovebox and,
in the air, the resulting precipitate was filtered, washed with pentane (5 x 3 mL), and dried under
reduced pressure to afford the oxidative addition complex.
PCy2 RuPhos
ir qir
Br Br
OA-A
Following the general procedure, a mixture containing 1,4-dibromobenzene (29.4 mg, 0.125
mmol), RuPhos (128 mg, 0.275 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (107 mg, 0.275 mmol)
was stirred at rt in cyclohexane (1.5 mL) for 12 h. General work-up afforded OA-A as a grey
solid (172 mg, 99%).
'H NMR (400 MHz, CD2 C 2) d 7.72 - 7.59 (m, 1H), 7.54 - 7.37 (m, 1H), 7.11 (d, J= 8.0 Hz,
1H), 7.02 (dd, J= 8.5, 1.9 Hz, 1H), 6.92 (dd, J= 7.0, 2.5 Hz, 1H), 6.70 (d, J= 8.5 Hz, 1H), 6.64
(t, J= 1.6 Hz, 1H), 4.66 (dt, J= 12.1, 6.1 Hz, 1H), 2.23 - 2.12 (m, 1H), 1.80 (br, 4H), 1.59 (br,
1H), 1.48 (s, 1H), 1.42 (d, J= 6.0 Hz, 3H), 1.32 - 1.12 (m, 2H), 1.05 (dd, J= 6.0, 3.7 Hz, 4H),
0.93 (t, J = 7.1 Hz, 1H). '3 C NMR (101 MHz, CD2 C1 2) d 159.08, 144.66, 144.48, 138.97,
138.93, 135.89, 135.12, 134.64, 134.15, 133.01, 132.66, 132.62, 132.51, 131.09, 130.96, 130.62,
130.60, 130.20, 129.17, 129.15, 126.40, 126.34, 126.06, 117.33, 107.47, 106.97, 71.09, 70.64,
34.12, 33.90, 33.63, 33.26, 28.23, 28.02, 27.71, 27.69, 27.35, 27.16, 27.03, 26.91, 26.84, 26.81,
26.72, 26.69, 26.03, 26.02, 22.33, 21.87, 21.38, 21.30, 13.81. (observed complexity is due to C-
P coupling). 3 1P NMR (121 MHz, CD2C 2) d 31.99. FT-IR (neat, cm-'): 2929.76, 2851.34,
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1453.14, 1383.05, 1373.23, 1269.20, 1227.14, 1105.13, 1066.00, 1037.87, 997.86, 850.63,
816.23, 742.05, 575.3. Anal. Caled. for C66HqoBr2O4P2Pd2: C, 57.36; H, 6.56. Found: C, 57.27;
H, 6.61.
I Me
PCy 2 M_ RuPhosIrOimr
~CI / 'CI
Me
OA-B
Following the general procedure, a mixture containing 1,4-dichloro-2,5-dimethylbenzene (20.0
mg, 0.125 mmol), RuPhos (133.3 mg, 0.275 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (111.0 mg,
0.275 mmol) was stirred at rt in THF (1.0 mL) for 12 h. General work-up afforded OA-B as a
light grey solid (133.5 mg, 89 %).
'H NMR (400 MHz, CD2Cl 2) d 7.71 (t, J = 8.4 Hz, 2H), 7.64 (t, J = 7.3 Hz, 2H), 7.45 (m, 2H),
7.40 (m, 2H), 6.87 (ddd, J = 7.5, 2.9, 1.5 Hz, 3H), 6.65 (d, J = 8.5 Hz, 2H), 6.60 (d, J = 8.4 Hz,
2H), 6.27 (br, 2H), 4.61 (m, 4H), 2.54 (s, 6H), 2.27 (m, 4H), 1.83 (m, 18H), 1.43 (m, 18H), 1.16
(m, 17H), 1.05 (m, 5H), 0.91 (d, J = 6.1 Hz, 6H). 13C NMR (101 MHz, CD 2Cl2 ) d 160.66,
159.65, 146.01, 145.83, 140.48, 135.81, 135.75, 135.38, 134.08, 134.03, 133.89, 132.78, 132.67,
131.14, 130.94, 126.78, 126.72, 111.18, 111.14, 107.07, 106.80, 71.69, 70.45, 35.57, 35.29,
32.47, 32.21, 31.12, 31.07, 29.61, 29.56, 27.95, 27.88, 27.80, 27.70, 27.53, 27.45, 27.10, 26.99,
26.77, 26.30, 22.77, 22.35, 22.25, 22.04 (observed complexity is due to C-P coupling). 31P
NMR (121 MHz, CD 2Cl 2) d 32.03. FT-IR (neat, cm'1): 2972.34, 2927.52, 2851.98, 1590.82,
1450.73, 1382.13, 1370.98, 1264.81, 1249.18, 1135.64, 1104.19, 1064.08, 1041.81, 1002.1,
898.23, 865.21, 848.18, 812.89, 767.71, 757.24, 744.88, 732.59, 667.8. HRMS (ESI) m/z caled.
for C68H94C1204P2Pd2 [M-Cl]*: 1285.4386. Found: 1285.4389.
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F i greRuPhos
OA-C B
Following the general procedure, a mixture containing 1,3-Dibromo-5-fluorobenzene (32 mg,
0.125 mmol), RuPhos (128 mg, 0.275 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (107 mg, 0.275
mmol) was stirred at rt in cyclohexane (1.5 mL) for 12 h. General work-up afforded OA-C as a
grey solid (157 mg, 90%).
'H NMR (400 MHz, CD2C 2) d 7.54 (t, J = 6.9 Hz, 1H), 7.48 (t, J = 8.4 Hz, 1H), 7.29 (dt, J
21.5, 7.4 Hz, 2H), 6.77 (ddd, J= 7.6, 3.0, 1.5 Hz, 1H), 6.54 (dd, J= 41.6, 8.4 Hz, 2H), 6.35 (d, J
= 9.4 Hz, 1H), 6.27 (s, 1H), 4.48 (ddt, J= 35.1, 12.2, 6.2 Hz, 2H), 2.36 (s, OH), 2.06 (s, 1H), 1.44
(s, 5H), 1.36 (d, J= 6.2 Hz, 3H), 1.18 (d, J= 6.0 Hz, 2H), 0.96 (d, J= 6.0 Hz, 2H), 0.85 (d, J=
6.1 Hz, 2H). '3 C NMR (101 MHz, CD2C 2) d 159.48, 158.46, 156.64, 144.44, 140.63, 135.28,
135.12, 132.74, 132.65, 132.54, 132.37, 130.96, 130.81, 130.79, 128.84, 126.52, 126.46, 123.09,
122.87, 113.35, 113.11, 110.48, 107.55, 107.07, 71.28, 71.04, 34.40, 29.10, 28.19, 27.21, 27.08,
26.91, 26.80, 26.68, 26.28, 26.03, 21.85, 21.78, 21.39, 21.26, 13.81. (observed complexity is due
to C-P coupling). 31P NMR (121 MHz, CD2 Cl2 ) d 31.10. '9F NMR (376 MHz, CD2 C 2) 6 -
119.28. FT-IR (neat, cm~'): 2927.02, 2849.68, 1590.32, 1569.92, 1536.95, 1464.97, 1448.21,
1387.36, 1376.81, 1276.85, 1250.56, 1184.18, 1112.72, 1062.63, 861.73, 831.04, 766.54, 748.1,
737.28, 709.96, 576.55. HRMS (ESI) m/z calcd. for C66H89C12FO4P2Pd2 [M-C]*: 1319.3496.
Found: 1319.3490.
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NF
PCy2 RuPhos
IPr Pr 
/Br
OA-D
Following the general procedure, a mixture containing 1,4-Dibromo-2,5-difluorobenzene (36
mg, 0.125 mmol), RuPhos (128 mg, 0.275 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (107 mg, 0.275
mmol) was stirred at rt in cyclohexane (1.5 mL) for 12 h. General work-up afforded OA-D as a
grey solid (150 mg, 85%).
'H NMR (400 MHz, CD2Cl 2) d 7.74 (q, J= 8.1 Hz, 1H), 7.66 (t, J= 7.5 Hz, 1H), 7.48 (dd, J=
18.1, 8.6 Hz, 2H), 7.25 (t, J= 8.3 Hz, 1H), 7.08 (dd, J= 6.5, 2.3 Hz, 1H), 6.94 - 6.83 (m, 1H),
6.76 (d, J= 9.8 Hz, 1H), 6.69 (d, J= 8.4 Hz, 1H), 6.62 (t, J= 8.9 Hz, 1H), 4.64 (dt, J= 12.2, 5.8
Hz, 2H), 4.45 (dt, J= 12.1, 6.0 Hz, 1H), 2.32 - 2.18 (m, 1H), 1.83 (br, 1H), 1.63 (s, 4H), 1.47
(br, 8H), 1.37 (d, J= 6.0 Hz, 3H), 1.13 (d, J= 6.0 Hz, 3H), 1.05 (d, J= 6.0 Hz, 2H), 0.98 (d, J=
6.0 Hz, 2H), 0.13 (s, 1H).' 3 C NMR (101 MHz, CD 2Cl 2) d 156.71, 136.37, 130.79, 128.21,
71.88, 71.12, 70.58, 37.54, 36.88, 26.91, 26.65, 26.52, 26.24, 25.95, 22.28, 21.82, 21.62, 21.43,
21.24, 0.75 (observed complexity is due to C-P coupling). 3 P NMR (121 MHz, CD2Cl 2) d
31.81. 'F NMR (376 MHz, CD2Cl 2) 6 -117.91. FT-IR (neat, cm-1): 2927.34, 2850.02,
1590.07, 1451.45, 1385.02, 1374.65, 1277.87, 1251.54, 1135.22, 1110.91, 1061.23, 866.25,
850.62, 765.31, 753.05, 737.00, 609.04. Anal. Calcd. for C6 6H8 8Br2F2 0 4P2Pd2 : C, 55.90; H,
6.26. Found: C, 55.90; H, 6.37.
CF3
PCy C RuPhos
iPr Or
F3C
OA-E
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Following the general procedure, a mixture containing 1,4-Bis(trifluoromethyl)-2,5-
dichlorobenzene (32 mg, 0.125 mmol), RuPhos (128 mg, 0.275 mmol), and (1,5-
COD)Pd(CH 2TMS)2 (107 mg, 0.275 mmol) was stirred at rt in cyclohexane (1.5 mL) for 12 h.
General work-up afforded OA-E as a grey solid (132 mg, 83%).
'H NMR (400 MHz, CD 2C 2) d 7.84 - 7.71 (m, 1H), 7.62 (q, J = 7.6 Hz, 1H), 7.45 (dq, J=
21.5, 7.1 Hz, 3H), 7.09 (s, 1H), 7.00 (s, 1H), 6.84 (dd, J= 16.4, 7.6 Hz, 1H), 6.65 (dd, J= 23.7,
8.5 Hz, 2H), 4.63 (dp, J= 18.1, 6.0 Hz, 3H), 1.82 (br, 8H), 1.48 (br 3H), 1.35 (s, 2H), 1.17 (s,
2H), 0.91 (dd, J= 17.4, 6.0 Hz, 4H). '3 C NMR (101 MHz, CD 2C 2) d 6 161.59, 161.35, 161.00,
160.94, 145.63, 145.45, 136.82, 136.30, 134.86, 134.46, 133.90, 132.23, 132.11, 131.90, 130.76,
130.73, 130.58, 126.43, 126.37, 107.85, 106.75, 106.65, 106.52, 106.36, 72.20, 71.63, 70.25,
70.16, 35.06, 34.78, 31.80, 31.54, 30.18, 27.41, 27.05, 26.91, 26.79, 26.72, 26.55, 26.50, 26.43,
26.34, 26.00, 25.86, 25.53, 25.45, 21.95, 21.81, 21.74, 21.35, 21.27, 21.23, 21.10. (observed
complexity is due to C-P coupling). 31P NMR (121 MHz, CD2 C 2) d 32.03. '9F NMR (376
MHz, CD 2CI2) 6 -54.53. FT-IR (neat, cm~'): 3855.14, 3745.16, 2923.80, 2856.75, 1589.64,
1560.57, 1444.39, 1334.44, 1252.70, 1154.35, 1093.12, 1067.17, 1047.83, 1020.47, 766.65.
HRMS (ESI) m/z caled. for C68H89CI204P2F6Pd2 [M-C]: 1391.3820. Found: 1393.3881.
PCy2 RuPhos
IPr r
Br Br
OA-G
Following the general procedure, a mixture containing 4,4-Dibromobiphenyl (39 mg, 0.125
mmol), RuPhos (128 mg, 0.275 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (107 mg, 0.275 mmol)
was stirred at rt in cyclohexane (1.5 mL) for 12 h. General work-up afforded OA-G as a grey
solid (209 mg, 98%).
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'H NMR (400 MHz, CD 2C 2) 6 7.63 (t, J= 8.4 Hz, IH), 7.41 (dt, J= 23.5, 7.4 Hz, 1H), 7.16 (d,
J= 8.1 Hz, 1H), 7.09 (dd, J= 8.4, 2.0 Hz, 1H), 6.87 (dd, J= 7.8, 2.9 Hz, OH), 6.65 (d, J= 8.5
Hz, 1H), 4.62 (p, J= 6.0 Hz, 1H), 2.18 (q, J= 12.3, 11.8 Hz, 1H), 1.71 (d, J= 52.0 Hz, 1H), 1.52
(s, 1H), 1.40 (d, J= 6.0 Hz, 3H), 1.21 (b, 1H), 1.03 (d, J= 6.0 Hz, 3H), 0.78 (q, J= 13.4 Hz,
1H). "C NMR (101 MHz, CD2C 2) d 159.02, 144.84, 144.67, 137.58, 137.55, 136.27, 134.46,
134.39, 133.71, 133.36, 132.48, 132.38, 131.04, 130.47, 130.44, 126.26, 126.21, 124.85, 124.83,
111.52, 111.48, 107.25, 70.86, 33.85, 33.59, 28.14, 27.99, 27.61, 27.59, 27.23, 27.10, 26.92,
26.88, 26.77, 26.02, 21.89, 21.38 bserved complexity is due to C-P coupling). 3 1P NMR (121
MHz, CD2 C 2) d 31.80. FT-IR (neat, cm'): 2976.53, 2920.64, 2849.62, 2354.67, 1588.59,
1455.66, 1242.77, 1110.89, 1059.83, 996.47, 797.70, 731.52, 667.91, 610.43, 577.71. HRMS
(ESI) m/z calcd. for C72H94Br2 O4P2Pd2 [M-2Br]2 : 649.2364. Found: 649.2390.
Pr r
OA-c CV RuPhos
Following the general procedure, a mixture containing 4-chlorophenyl ether (60 mg, 0.125
mmol), RuPhos (292.8 mg, 0.275 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (244 mg, 0.275 mmol)
was stirred at rt in cyclohexane (2.4 mL) for 12 h. General work-up afforded OA-I as a light
brown solid (304.3 mg, 88 %).
'H NMR (400 MHz, CD 2C 2) d 7.67 (q, J = 7.7, 7.0 Hz, 1H), 7.45 (dt, J = 23.0, 7.4 Hz, 1H),
7.01 (dd, J= 8.7, 2.0 Hz, 1H), 6.90 (ddd, J= 7.6, 3.0, 1.4 Hz, 1H), 6.67 (dd, J= 8.5, 3.7 Hz, 3H),
4.66 (p, J= 6.0 Hz, 1H), 2.20 (q, J= 12.1 Hz, 2H), 1.81 (br, 3H), 1.61 (br, 1H), 1.42 (d, J= 6.0
Hz, 3H), 1.27 (b, 2H), 1.05 (d, J= 6.0 Hz, 3H), 0.78 (q, J= 12.9 Hz, 1H). '3 C NMR (101 MHz,
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CD 2C1 2) d 159.16, 154.65 145.05, 144.88, 137.00, 136.96, 134.81, 133.90, 133.54, 132.37,
132.26, 130.95, 130.55, 130.52, 129.45, 126.28, 126.22, 117.46, 117.43, 110.90, 110.87, 106.91,
70.75, 33.67, 33.40, 28.12, 27.71, 27.69, 27.24, 27.11, 26.84, 26.72, 26.00, 21.83, 21.34
(observed complexity is due to C-P coupling). 31P NMR (121 MHz, CD 2Cl 2) d 33.45. FT-IR
(neat, cm-): 2923.66, 2849.80, 1591.49, 1471.28, 1456.00, 1435.99, 1383.09, 1371.62, 1225.85,
1164.77, 1111.35, 1050.67, 1004.19, 848.86, 809.35, 784.21, 758.68, 731.48, 609.16, 575.02,
564.82. Anal. Caled. for C72H94C1205P2Pd2 : C, 62.43; H, 6.84. Found: C, 62.33; H, 6.82.
Me
O~r PCYr
C1 Me
OA-J RuPhos
C
Following the general procedure, a mixture containing 4,4'-oxybis(1-chloro-3-methylbenzene)
(21.9 mg, 0.125 mmol), RuPhos (96.0 mg, 0.275 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (80.0 mg,
0.275 mmol) was stirred at rt in cyclohexane (0.75 mL) for 12 h. General work-up afforded OA-
J as a brown solid (86.6 mg, 75 %).
'H NMR (400 MHz, CD 2CI 2) d 7.67 (q, J = 7.6, 6.7 Hz, 1H), 7.45 (dt, J = 23.0, 7.4 Hz, 1H),
6.95 (s, 1H), 6.90 (ddd, J= 7.6, 2.9, 1.3 Hz, 1H), 6.78 (d, J= 8.3 Hz, 1H), 6.67 (d, J= 8.5 Hz,
IH), 6.37 (d, J= 8.4 Hz, 1H), 4.66 (p, J= 6.0 Hz, 1H), 2.18 (s, 2H), 1.78 (s, 4H), 1.47 (s, 1H),
1.25 (s, 1H), 1.05 (d, J= 6.0 Hz, 3H), 0.78 (br, 1H). "C NMR (101 MHz, CD 2Cl2) d 159.61,
153.10, 145.62, 145.45, 139.16, 135.24, 134.91, 134.88, 134.86, 134.55, 134.19, 132.94, 132.84,
131.51, 131.06, 131.04, 129.47, 127.70, 126.82, 126.77, 116.76, 111.74, 107.51, 71.32, 34.22,
33.93, 28.69, 27.90, 27.77, 27.48, 27.45, 27.34, 26.64, 22.43, 21.91, 16.36 (observed complexity
is due to C-P coupling).3 1P NMR (121 MHz, CD2Cl 2) d 33.23. FT-IR (neat, cm' ): 2972.95,
2927.54, 2852.92, 1592.71, 1453.1, 1382.83, 1371.1, 1267.8, 1230.18, 1173.8, 1112.72, 1054.44,
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1002.37, 898.56, 848.98, 803.64, 785.06, 756.54, 735.1, 667.84. Anal. Calcd. for
C74H98C1205P2Pd2 : C, 62.89; H, 6.99. Found: C, 62.77; H, 6.94.
Linear Peptide Synthesis
General Linear Peptide Synthesis Procedure:
The peptides (P1-P4) were synthesized on a 0.9 mmol scale using manual Fmoc-SPPS (Solid
Phase Peptide Synthesis) chemistry. Specifically, the resin was pre-wetted with DMF in a
peptide synthesis vessel equipped with a T-bore stopcock connected to a vacuum pump for faster
drainage. Each amino acid (5 mmol) was pre-dissolved in HBTU (0.2 M, 25 mL). The procedure
for each amino acid coupling cycle included: 1) pre-activation of the amino acid with DIEA (2.5
mL; note, 0.9 mL was used in the case of cysteine to prevent racemization); 2) 10 min coupling
time; 3) Wash with DMF (4 x 30 mL; or enough DMF to cover the resin); 4) Deprotection with
20% (v/v) piperidine in DMF (2 x 3 min; 30 mL each time, or enough of the solution to cover
the resin); 5) Wash with DMF (4 x 30 mL; or enough DMF to cover the resin). After completion
of the stepwise SPPS, the resin was washed thoroughly with CH2Cl 2 and dried under vacuum.
Peptides P1, P2, P3, and P4 were cleaved from the resin and deprotected on the side-chains by
treatment with 2.5% (v/v) water, 2.5% (v/v) 1,2-ethanedithiol (EDT), and 1% (v/v)
triisopropylsilane in neat trifluoroacetic acid (TFA) for 7 min at 60 'C (water bath, 5 mL
cleavage solution/250 mg of final resin). Cold (-80 'C) diethyl ether was added to the solution
and the resulting precipitate was centrifuged at 4000 rpm for 5 min. The residue was washed
with cold ether (2x). The obtained solid was dissolved in 50% H20 : 50% acetonitrile containing
0.1% TFA, the resin was removed via filtration and the final solution was lyophilized to provide
the crude peptide material. For peptides containing biotin, the unnatural amino acid Fmoc-
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Lys(biotin)-OH was used as the coupling amino acid. The following peptides were all
synthesized using this procedure:
Peptide =P1 NH2
H 0 H 
0H
NH 0 H 0  H 0 "C 0 0HH SH H H HN H N N N -- NO N H
NH2 H 0 .H 0 0 O H 0 O H 0
NH 2  NH 2
Peptide = P2
N =\ \ NH2
N H NH2
H H HOA H H
HN OH
0 0 0~~IO H 0~NH
Peptide =P3 NH2  HN - NH
o OH S...
NH2 HH H P 0 0 H H
HSH S H OH H
NH 2  NH2
Peptide = P24 NH2  NH2
NOH N NA N N-NN -NNH2
H H ~.H o H) H H4
HO O OOH H < O H
OH NH 2  HN NH
Peptide Purification
Solvent compositions for RP-HPLC purification are water with 0.1% TFA (solvent C) and
acetonitrile with 0.1% TFA (solvent D). The crude peptide was dissolved in 50% C : 50% D and
purified by semi-preparative RP-HPLC (Agilent Zorbax 300SB C18 column: 21.2 x 250 mm, 7
jm, linear gradient: 5-50% B over 65 min, flow rate: 5 mL/min). Each HPLC fraction was
analyzed by mass-directed preparative LC-MS. HPLC fractions containing pure product were
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further confirmed by LC-MS, combined, and lyophilized. Peptides synthesized using manual
SPPS and purified by RP-HPLC are listed in Table Si.
Table S1. Sequences and masses of peptides synthesized by manual fast flow SPPS.
Observed
Calculated
Peptide Sequencea Mass [M+H]*
mass
or [M+H]2+
Pi NH2-ITFCDLLCYYGKKK-CONH 2  1692.87 1693.89
P2 NH2-LTFCHYWAQLCS-CONH 2  1469.66 1470.69
P3 NH2-ITFCDLLCYYGKKKK(Biotin)-CONH 2 2047.05 1025.04
P4 NH2-YLICYTDCGFLKKKK(Biotin)-CONH 2 2047.05 1025.05
a Cysteine residues are highlighted in red.
P1:
[M+2H]
847.44[S2+1
1000
M+H] 4
693.89
I I
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Time (min)
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P2:
2+[M+2H]
735.85 [M+H]1 +1470.69
800
I
1400
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P3:
3+[M+3H]
683.69 [M+2H]
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3+[M+3H]
683.69 [M+2H]21025.051
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General Macrocyclization Procedure
rti
PrO -
2L sM 2
H-12N C(O)NH 2
100 AM
0.1 M Tris (pH 7.5)
CHsCN: H 20 (1:1)
30 min
then C2
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I
P4:
I
8.5
112N C(O)NH 2
A solution of the Pd-stapling reagent in acetonitrile (400 mM) was added to a solution of
peptide (200 mM) in Tris buffer (0.1 M, pH 7.5). Note: if the palladium reagent was not readily
soluble in CH3CN, the slurry was sonicated for 30 s to facilitate this process. Final conditions:
[Pd] = 200 mM; [peptide] = 100 mM; H2 0 : CH3CN = 1 : 1. After 30 min stirring at rt, 3-
mercaptopropionic acid (3 equiv to the palladium complex, solution in 1 mL of H20) was added
to the reaction mixture to quench and remove some of the remaining palladium species. The
reaction was allowed to stand for 1 h for precipitate formation, the solids were centrifuged at
4000 rpm for 5 min followed by washing with an additional 5 mL of 50 %: 50 % CH3CN : H20
(v/v). The supernatant was collected via decantation and the acetonitrile was removed via rotary
evaporation and the resulting crude material was lyophilized. The crude peptide was purified
using preparative HPLC as described above.
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LC-MS Traces of Crude Reaction Mixtures of Macrocyclization Experiments (for P1)
M+3H1) M+2H]+ Pd-species620.98 930.46 decomposition
Pdt by-products
800 100
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. 5 88
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6 0 800 Pdt
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LC-MS Traces for Isolated Pure Macrocvclic Peptides (for P1)
[M+3H]3+  2+
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LC-MS Traces of Crude Reaction Mixtures of Macrocyclization Experiments (for P2)
3+
M+3H] 2+ Pd-specIes
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LC-MS Traces for Isolated Pure Macrocyclic Peptides (for P2)
[M+2Hf1 1+
818.20 [M+H]
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800 1200 1600
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LC-MS Traces for Isolated Pure Macrocyclic Peptides (for P3)
3+
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C-CA Protein Expression
This procedure and vector was obtained based on a previously reported protein expression.3 Full-
length HIV1 Core Antigen was obtained from Invitrogen. C-CA sequence was cloned into pET-
SUMO plasmid and ligated with T4 ligase overnight at 4 'C. The resulting construct was
transformed into DH5a cells and then purified with the QlAprep Spin Miniprep Kit. BL21 DE3
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competent cells were transformed via heat shock with 100 ng of plasmid containing properly
oriented C-CA inserts. Single transformed colonies were grown in IL LB broth containing 30
tg/mL kanamycin. The cultures were induced with 1 mL 0.4 M IPTG upon reaching OD600
0.6.
Following overnight expression, cells were pelleted and resuspended in 50 mL Tris buffer (50
mM Tris, 150 mM NaCl, pH 7.4) containing 20 mg lysozyme, 2 mg DNAse I, and a half tablet
of cOmplete Mini protease inhibitor cocktail (Roche Life Science). Following sonication, the
suspension was pelleted (25 min, 17000 rpm) and supernatant loaded onto a Ni-NTA column
(HisTrap FF crude, GE Healthcare). The column was washed with 30 mL of Tris buffer (pH 8.0)
and 40 mM imidazole in Tris buffer (pH 8.0) each and the SUMO-CCA fusion protein was
eluted in 10 mL 150 mM imidazole in Tris buffer (pH 8.0). The protein was then subject to
buffer exchange on Akta size exclusion column FPLC into Tris buffer at pH 7.4.
Protein concentration was determined by measuring absorbance at 280 nm (MW = 22916.9 Da, c
= 9970 as found on ExPASy ProtParam (http://web.expasy.org/protparam/)); SUMO cleavage
was subsequently performed by incubating SUMO-CCA overnight at 4 'C with 1 ng SUMO
protease per 1 mg protein. The resulting mixture was loaded onto a Ni-NTA column and washed
with 10 mL 40 mM imidazole in Tris buffer (pH 8.0) to isolate C-CA. The protein was subjected
to buffer exchange into Tris buffer at pH 7.4, concentrated over a 3000 Da Amicon Ultra-15
Centrifugal Filter Unit (EMD Millipore), analyzed by HPLC-MS, and flash frozen in liquid
nitrogen for long-term storage at -80 'C.
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Figure S2: Deconvoluted spectrum of CCA protein after purification
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Calculated molecular weight: 9518.9 Da. Found: 9519.39 Da.
BioLayer Interferometry Binding
Experimental Design
Binding kinetics for the C-CA/P3-A - P3-K interaction were measured on Octet RED96
instrument from ForteBio. All measurements were performed at 30' C in a 96-well plate shaking
at 1000 rpm. In general, streptavidin-coated tips (from ForteBio) were dipped in binding buffer
(lx phosphate buffered saline, 0.1% w/v bovine serum albumin, 0.02% tween-20, pH 7.4) for 10
min to remove sucrose coating. A typical experiment consisted of five steps:
- Base line reading. Tips were dipped into a well containing fresh binding buffer
for 60 sec.
- Ligand loading. ~45 pM solutions of P3,4-A - P3,4-K in binding buffer were
associated onto the tips for 90-300 sec.
- Base line reading #2. Tips were dipped into a well containing fresh binding
buffer for 90-120 sec.
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750 1000(m/z)
- Association. P3 and P4 loaded tips were dipped into wells containing variable
concentrations of C- CA (5 pM - 100 gM) in binding buffer for 90-300 sec.
- Dissociation. The tips were dipped back into wells containing binding buffer
only for 300 sec or until the response decreased back to the base line level. Double
referencing using wells containing no C-CA and tips loaded with no ligands was used to
subtract the background.
Data Analysis
Binding data collected for peptides P3-A-K and P4-A, K according to the procedure
described in the section above was processed as follows. Reference readings were subtracted
universally from both association and dissociation curves. Association curves were aligned to
the last five sec of the base line, and dissociation curves were aligned to the last value of
association curves. No curve-smoothing filtering was performed. The KD values reported
were calculated using the automated software for the Forte Bio-Layer Interferrometry
software manual. The curves and subsequent fittings have been provided below for each
peptide, as well as a table with the calculated binding values.
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The peptides (~I mg) were dissolved in 1 mL of DMSO and injected onto various HPLCs for
biomimetic analysis of the physicochemical properties presented below. Relevant information
regarding each method has been described below.
Lipophilicity measurements: A method has been described by Kerns et att for a quick HPLC
method to estimate the logarithm of the octanol-water partition coefficient at pH 7.4.
Instrument
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Materials:
HPLC grade acetonitrile
HPLC grade Water
Ammonium Acetate
pH 7.0 Buffer solution
50 mM Ammonium acetate pH 7.4
1 M NaOH solution
Diluent:
70% MeCN / 30% water
Analytical Column:
5cm x 4.6mm Polaris C18 5 tm HPLC column
Detection:
UV -230nm
Experimental:
Mobile Phase
Line A: 100% MeCN
Line B : 50mM ammonium acetate adjusted to pH 7.4 using IM NaOH solution.
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HPLC Gradient
Time % Mobile % Mobile Phase Flow Rate (mL min-')
Phase A B
0 0 100 1.0
2.5 95 5 1.0
4.0 95 5 1.0
4.1 0 100 1.0
6.1 0 100 1.0
Column Temperature: 40'C
Injection volume: 2 1iL
Phospholipid affinity measurements: A method has been described by Valko et a15 for a quick
HPLC method to characterize the interactions of drugs with immobilized artificial membrane
(IAM). With a set of standards, the gradient retention times can be converted to
Chromatographic Hydrophobicity Index values referring to IAM chromatography (CHIIAM)
that approximates an acetonitrile concentration with which an equal distribution of compound
can be achieved between the mobile phase and IAM.
Calibration standards:
Acetophenone, Propriopheneone, Valerophenone and Octanophenone made up at concentration
of ~1 mg mUl using the diluent.
Diluent:
70% MeCN / 30% water
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Analytical Column:
Regis 10 cm x 4.6mm IAM PC 10 ptm HPLC column
Detection:
UV -230 nm
Experimental:
Mobile Phase
Line A: 100% MeCN
Line B : 50 mM ammonium acetate adjusted to pH 7.4 using IM NaOH solution.
HPLC Gradient
Time % Mobile % Mobile Phase Flow Rate (mL min-)
Phase A B
0 0 100 1.0
6.0 100 0 1.0
6.5 100 0 1.0
7.0 0 100 1.0
9.0 0 100 1.0
Column Temperature: 40'C
Injection volume: 2 pxL
Human Serum Albumin (HSA) binding measurements: A fast gradient HPLC method (cycle
time 15 min) is described by Valko et a16 to determine Human Serum Albumin (HSA) binding of
discovery compounds using chemically bonded protein stationary phases. The HSA binding
values were derived from the gradient retention times that were converted to the logarithm of the
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equilibrium constants (logKHSA) using data from a calibration set of molecules. A calibration
graph is plotted with logarithm of the retention time vs logKHSA (Valko et al).
Calibration standards:
Carbamazapine, Nicardipine, Warfarin, Diclofenec and Ketoprofen sample solutions made up at
concentration of ~1 mg mL~1 using the diluent, respectively.
Diluent:
70% MeCN / 30% water
Analytical Column:
5 cm x 3.0 mm HSA 5tm HPLC column
Detection:
UV -280 nm or 230 nm
Experimental:
Mobile Phase
Line A : 50 mM ammonium acetate adjusted to pH 7.4 using IM NaOH solution.
Line B : 100% IPA
HPLC Gradient
Time % Mobile % Mobile Phase Flow Rate (mL min')
Phase A B
0 100 0 1.2
4.5 70 30 1.2
9.0 70 30 1.2
9.5 100 0 1.2
14 100 0 1.2
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Column Temperature: 40'C
Injection volume: 2 tL
The predicted volume of distribution was calculated from the following equation based on HSA
binding and phospholipid affinity values corresponding to values reported by Valko et a16 .
Log VD = 0.44( 0.02) log K (IAM) - 0.22( 0.02) log K (HSA) - 0.66
ICP-MS Analysis
Two distinct macrocyclic peptides, chosen at random (P2-C and P1-A), were dissolved in 0.4
mL of concentrated nitric acid. This solution was sonicated and diluted with MilliQ pure water to
0.2% nitric acid concentration. ICP-MS was performed on the resulting mixtures. Calibration
curves were generated using Pd ICP-MS standards for a range between 1000 ppm and 100 ppb.
There was no palladium found to be remaining in the peptide after purification. Initial palladium
content was ~300 ppm used to perform the macrocyclization reactions indicating over 99%
palladium removal.
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Chapter 2. Water-Soluble Palladium Reagents for Cysteine S-Arylation under Ambient
Aqueous Conditions
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2.1 - Introduction:
Methods for the chemical modification of amino acids serve as fundamental tools for
research at the interface of chemistry and biology and play an important role as enabling
technologies for the pharmaceutical and materials sciences. Important applications
include the preparation of probe molecules for the study of protein function,I the
development of new protein-drug conjugates,2 nanomedicines with unique therapeutic
properties, 3 and the incorporation of biological macromolecules in functional hybrid
materials.4 Ideally, broadly applicable protocols to modify amino acids for bioconjugation
are processes that are chemoselective, proceed at a high rate under mild reaction
conditions (i.e. aqueous solvents/buffers, pH 6-8, temperature < 37 'C), and are tolerant
to the functional group diversity present in complex biomolecules. In addition, such a
process should forge stable chemical bonds in a modular manner that provides access to
structural diversity.5'6 The preparation of protein bioconjugates dates back over a
century,7 however, few reports exist which meet all of these specifications.
With these criteria in mind, we previously reported a palladium-mediated method that
can be used for the reliable and rapid S-arylation of cysteine residues in peptides and
proteins.8 This method is highly chemoselective for cysteine among other nucleophilic
residues, as confirmed by MS/MS analysis, and can be used without incorporation of
unnatural amino acids. One notable limitation of this procedure, however, was the
necessary addition of an organic cosolvent (N,N-dimethylformamide, dimethyl sulfoxide,
or acetonitrile) to dissolve the organometallic reagents. These organic cosolvents have the
potential to denature sensitive biomolecules, limiting the scope and utility of our
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approach. To address this limitation, we sought an improved, cosolvent-free protocol for
bioconjugation employing modified, water-soluble palladium complexes.
Figure 2: S-arylation of biomolecules under ambient aqueous conditions. This work
expanded on previous reports of Palladium-mediated S-arylation chemistry by using a water-
soluble ligand to facilitate bioconjugation under benign and fully aqueous conditions.
OH SH COOH neutralpH
M Me PCY 2  H 2N blomolecule C(O)NH 2 rapid bfe H 
S COOH
H 2N NH room temperature H 2N blomolecule C(O)NH 2X NH chemoselective H 2N NHNaO3S NH N :/ H NH
NH N /(sSPhos)Pd(Ar)X
water-soluble peptides, proteins benign aqueous S-arylation productsoxidative addition petds rtisconditions
complexes
= affinity tags, fluorophores, bioconjugate handles, aromatics
Our group reported the synthesis of a sulfonated ligand, sodium 2'-
dicyclohexylphosphino-2,6-dimethoxy-1,1'-biphenyl-3-sulfonate hydrate (sSPhos), which
has been utilized in the context of Suzuki-Miyaura couplings in water.9 We hypothesized
that palladium(II) complexes supported by this ligand might be sufficiently water-soluble
to serve as arylation reagents for cysteine-containing biomolecules under completely
aqueous conditions. To test this hypothesis, both a model peptide, and a designed ankyrin
repeat protein (DARPin), each containing a single cysteine residue, were exposed to an
sSPhos supported palladium reagent in a completely aqueous environment (Figure 2). We
chose the DARPin protein to ensure the comparison in ligand-enhanced reactivity directly
paralelled our previous study.8 In both cases, the product of cysteine arylation was formed
rapidly at room temperature with high chemoselectivity. In contrast, use of the complexes
supported by RuPhos and SPhos ligands, under these cosolvent-free conditions, provided
<20% yield. These results are consistent with the idea that the sulfonate group of sSPhos
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allows the palladium reagent to be more soluble in water and, therefore, able to react with
cysteine residues more efficiently.
Figure 3: Initial ligand screen. Examining effect ligand imposes on efficiency of
palladium-mediated unprotected cysteine bioconjugation under ambient aqueous
conditions. aYield determined by LC-MS analysis. bYield determined by deconvolution of
mass spectrum.
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2.2 - Results and Discussion:
In our previous report, the palladium reagents were prepared in a nitrogen-filled
glovebox, presenting a potential barrier for adoption by laboratories without routine
access to a glovebox. To ameliorate this situation, we investigated the preparation of
several sSPhos-ligated palladium complexes employing a bench top protocol, without the
exclusion of moisture or oxygen from the reaction mixture (see Experimental for details).
Under these conditions, it was found that a mixture of aryl halide (ArX), ligand, and
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[(1,5-COD)Pd(CH 2TMS) 2] dissolved in tetrahydrofuran (THF) afforded the desired
palladium complexes in excellent yields after an hour of stirring (Table 1) and subsequent
filtration. These easily purified arylation reagents, sSPhosPd(X)Ar, are air-stable and be
stored under ambient atmosphere and temperature for over 12 months without displaying
noticeably diminished reactivity.
Table 1: Preparation of Air-Stable, Storable Palladium Reagents of Interest in
Chemical Biologya and subsequent S-arylation of an unprotected peptide . aReported
isolated yields are an average of two runs after purification. bS-arylation conversions
determined by LC-MS analysis of the crude mixture, see SI for details.
+ -~.TMS meo
,/f'jI" .. TMS sSPhos .1 equiv) NaO 3S X A-Y
X = OTf, Cl, Br 1h
... . .. .. . . . uiv rt, 1 h (sSPhos)Pd(X)Ar
SH TRIS buffer(pH 7.5, 0.1 M),
H2N unprotected peptide H + MeO A = " rt s
NH2 a3 5min, rt0
NaO3S quench with H2N -unprotected peptdeP3: NH 2-TDEYCKSR-C(O)NH 2  OA-Y 3-thioproplonic acid NH2
10 AM 20 pM P3-Y
name Ar X solatedyield of OA (%) S-arylation (%/A
0 0
O'A-20 OTf 94 99
H
C cooi
O -2 .. Br 99 99
OA-22 0 Cl 86 99
OA-23 Br 82 99
OA-24 N ci 94 99
OA-25 F Br 99 99
F
90
mi
In order to showcase the utility of this process for application in chemical biology,
several types of biologically relevant arylation reagents were isolated in high yield using
this procedure (Table 1) including examples that contain a fluorescein dye (OA-20), a
biotin labeling reagent (OA-21), and an aldehyde or an alkyne as bioconjugation handles
for further diversification (OA-22,23). Additionally, a heterocycle-containing reagent
(OA-24) and one containing a fluoroaromatic group (OA-25) were prepared in good to
excellent yield. Each of these reagents, regardless of complexity, displayed similar
reaction profiles with biomolecules containing cysteine (Table 1, Figure 3), highlighting
the generality of this palladium-mediated S-arylation approach. Additionally, P3-1 was
generated on a larger scale, 8 mg of starting peptide, and subsequent purification by
reverse-phase HPLC provided an isolated yield of 81% (see Experimental for details)
indicating that these modified peptides can be obtained in measurable quantities with high
efficiency.
Peptide macrocyclization is a burgeoning area in chemical biology and in the
development of new therapeutics.' 0"' Compared to their linear counterparts, peptide
macrocycles have been shown to exhibit enhanced cell permeability,1 2 increased target
binding affinity,' 3 and resistance to proteolytic degradation.1 4 As such, several methods
have been developed to bridge natural and unnatural amino acid residues along a peptide
chain.1 5 Notably, many of these methods utilize the same cross-linker structures with few
examples reported that introduce structural diversity at a late stage.1 6 Methods that allow
a divergent array of cross-linker structures to be used would better equip researchers to
investigate structure activity relationships and manipulate the biological activity of
peptide macrocycles. Towards this end, we recently published a report detailing the
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Figure 4: Reaction Characterization. LC-MS spectra depicting the reaction of an
unprotected peptide with an sSPhos-ligated palladium biotin complex (OA-21) and the
control reaction mixture without addition of peptide. All palladium reagents allowed for
rapid transformation of biomolecules exhibiting similar reaction profiles and near-
quantitative conversion. aYield determined by LC-MS analysis of the crude mixture, see
Experimental for details.
0 H N-f0
HN 'H 
S TRIS buffer S H
SH (pH 7.5, 0.1 M)
... H H20HN unprotected p + 0 PCy 2  HN NH 5 min rt S
NH, mo -- NH O quench with 0
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1 200 4 t 6 71i 11
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decomposition
control reaction by-products
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binding and pharmacokinetic differences that result from cross-linker manipulation
utilizing bis-palladium reagents for macrocycle diversification. 7 It was found that a
solution of 50% acetonitrile was required in order to dissolve the palladium reagents and
obtain high conversion efficiencies.
We set out to determine whether our previously described method could be carried
out without the aid of an organic cosolvent using sSPhos-derived oxidative addition
complexes. Thus, we prepared 13 bis-palladium macrocyclization reagents
([(sSPhos)Pd(X)] 2Ar) of varying structure, functional group presence, substitution
pattern, and conformation (Scheme 1) from commercially available aryl dihalides. We
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Scheme 1: Preparation of bis-Palladium Macrocyclization Reagentsa. aReported
isolated yields are an average of two runs after purification.
X TMS sSPhos (2.2 equiv) PCy 2
A TMS THF MeO OMeX 1-TMS J3-
X=Br 2.2 equiv rt, 1 h .Na[3S A 2 OA-Y1 equiv [(sSPhos)Pd(X)] 2Ar
1-0-1
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isolated yield: 96%
OH
OA-11
X=Br
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SA
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isolated yield: 99%
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X=Br
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NH 2
OA-12
X=Br
ed yield: 99% isolate
N
A-13
X=Br
d yield
O OH
OA-17
X=Br
isolated yield: 99%
OA-9
X=Br
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MeO
OMe
OA-14
X=Br
:99% isolated yield: 82%
O H
OA-18
X=Br
isolated yield: 99%
OA-10
X=Br
isolated yield: 98%
H
OA-15
X=Br
isolated yield: 88%
OA-19
X=Br
Isolated yield: 99%
chose these, in most instances, to be structurally different than the examples we
previously published. We note that regardless of these structural features, each of the bis-
palladium macrocyclization reagents could be isolated in good to excellent yield (82-99%
yield).
The high functional group tolerance of the cysteine arylation method may provide a
general method for the tuning of macrocyclic peptides. To test the efficiency of peptide
macrocyclization using sSPhos supported reagents, a model peptide (P2) was prepared
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with two cysteines separated in an i, i+7 position. After dissolving the peptide in water
and tris(hydroxymethyl)aminomethane (TRIS, pH 7.5), the palladium reagents were
introduced in an aqueous solution, and the mixture was gently vortexed for five seconds.
The reactions were allowed to proceed for ten minutes at room temperature, followed by
addition of 3-thiopropionic acid to quench the reaction, and LC-MS analysis indicated
that most of the macrocyclization reactions were high yielding under these standard
conditions (Scheme 2).
Scheme 2: Macrocyclization of Peptides Containing Two Unprotected Cysteinesa.
aYield determined by LC-MS analysis. bRequired 15% acetonitrile solution to fully
dissolve bis-palladium reagents
SH HS; F-&
_ 
0_2 TRIS (pH 7.5)
H2 N -unprotected peptlde-C(O)NH 2 + MeO H2 0 H2N unprotected peptide C(O)NH2
NX rt, 10 min
NaO3S
.2
1 equiv 2 equiv
P2: NH 2-ACYKRSDFTCGGGS-C(O)NH 2  OA-Y P2-Y
P2-7: 91% P2-8: 99 %b P2-9: 99 %b P2-10: 9 9%b
OH NH 2  MeO H
OMe
P2-11: 80% P2-12: 80% P2-13: 97% P2-14: 99% P2-15: 99 %b
0 OH 0 H
P2-16: 99%b P2-17: 100% P2-18: 99% P2-19: 99%b
In approximately half of the examples, full conversion was not observed under our
standard conditions (P2-8, 9, 10, 15, 16, and 19). In these cases, the addition of a small
amount of acetonitrile (15% by volume) was found to be beneficial, allowing reactions
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previously capped at 60% yield to reach full conversion (see Experimental). We believe
this is necessitated by the enhanced hydrophobicity of some of these macrocyclization
reagents. The macrocyclic peptide products are readily purified through reverse-phase
high performance liquid chromatography. ICP-MS analysis of the peptides showed that
more than 99% of palladium was removed during the purification process. Moreover, no
side reactions forming peptide oligomers through intermolecular cross-linking were
observed (see Experimental).
2.3 - Conclusion:
In summary, we have developed a general method for the S-arylation of cysteine on
biomolecules using bench-stable and water-soluble palladium reagents, prepared without the
exclusion of air or ambient moisture. In most instances, no organic cosolvent was necessary. Key
to the improvement of this method was the application of the commercially available sulfonated
biaryl dialkyl phosphine ligand sSPhos to the synthesis of palladium arylation reagents. Given
the importance of developing bioconjugation methods that adhere to physiological reaction
conditions, we anticipate that the availability of a water soluble Pd arylation reagent will
facilitate the adoption of this methodology by chemical biologists and medicinal chemists for the
synthesis of peptide macrocycles, antibody-drug conjugates, modified proteins, and other
biochemical probes.
2.4 - Experimental:
General Reagent Information
1 -[Bis(dimethylamino)methylene]- 1 H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide
hexafluorophosphate (HATU), D-Biotin, Fmoc-Rink amide linker, Fmoc-L-Gly-OH, Fmoc-L-
Leu-OH, Fmoc-L-Lys(Boc)-OH, Fmoc-L-Ala-OH, Fmoc-L-Cys(Trt)-OH, Fmoc-L-Gln(Trt)-OH,
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Fmoc-L-Asn(Trt)-OH, Fmoc-L-Glu(OtBu)-OH, Fmoc-L-Arg(Pbf)-OH, Fmoc-L-Phe-OH, Fmoc-
L-Ser(tBu)-OH, Fmoc-L-Thr(tBu)-OH, Fmoc-L-Tyr(tBu)-OH, and Fmoc-L-His(Trt)-OH were
purchased from CreoSalus, Inc (Louisville, KY). Peptide synthesis-grade NN-
dimethylformamide (DMF), dichloromethane (CH2 Cl 2), diethyl ether, HPLC-grade acetonitrile,
and guanidine hydrochloride were obtained from VWR International (Philadelphia, PA). Aryl
halides and aryl trifluoromethanesulfonates were purchased from Aldrich Chemical Co., Alfa
Aesar, or Matrix Scientific and were used without additional purification. All deuterated solvents
were purchased from Cambridge Isotopes and used without further purification. All other
reagents were purchased from Sigma-Aldrich and used as received.
All reactions with peptides were set up on the bench top and carried out under ambient
conditions. Anhydrous THF, pentane, cyclohexane, and acetonitrile were purchased from
Aldrich Chemical Company in SureSeal* bottles and were purged with argon before use.
All small-molecule organic and organometallic compounds were characterized by 'H, 13 C NMR,
and IR spectroscopy, as well as elemental analysis or high-resolution mass spectrometry (unless
otherwise noted). 3P NMR spectroscopy was used for characterization of palladium complexes.
Copies of the 'H, 13C, and 31P NMR spectra can be found at the end of the Supporting
Information. Nuclear Magnetic Resonance spectra were recorded on a Bruker 400 MHz
instrument and a Varian 300 MHz instrument. Unless otherwise stated, all 'H NMR experiments
are reported in 6 units, parts per million (ppm), and were measured relative to the signals of the
residual proton resonances methanol-d4 (4.78 and 3.31 ppm) in the deuterated solvents. All 13 C
NMR spectra are measured decoupled from 'H nuclei and are reported in 6 units (ppm) relative
to methanol-d 4 (49.30 ppm), unless otherwise stated. All 3 'P NMR spectra are measured
decoupled from 'H nuclei and are reported relative to H3PO 4 (0.00 ppm). All FT-IR spectra were
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recorded on a Thermo Scientific - Nicolet iS5 spectrometer (iD5 ATR - diamond). High
resolution mass spectra were obtained on a Bruker Daltonics APEXIV 4.7 Tesla Fourier
transform ion cyclotron resonance mass spectrometer (FT-ICR-MS).
LC-MS chromatograms and associated mass spectra were acquired using Agilent 6520
ESI-Q-TOF mass spectrometer. Solvent compositions used in the LC-MS are 0.1% formic acid
in H20 (solvent A) and 0.1% formic acid in acetonitrile (solvent B). The following LC-MS
method was used:
Method A LC conditions: Zorbax 300SB C3 column: 2.1 x 150 mm, 5 ptm, column temperature:
40 0C, gradient: 0-3 min 5% B, 3-8 min 5-95% B, 8-9 min 95% B, flow rate: 0.8 mL/min. MS
conditions: positive electrospray ionization (ESI) extended dynamic mode in mass range 300 -
3000 m/z, temperature of drying gas = 350 'C, flow rate of drying gas = 11 L/min, pressure of
nebulizer gas = 60 psi, the capillary, fragmentor, and octapole rf voltages were set at 4000, 175,
and 750, respectively.
Determination of Bioconjugation and Macrocyclisation Yields
Data were processed using Agilent MassHunter software package. All reported yields
were determined by integrating total ion current (TIC) spectra. First, the peak areas for all
relevant peptide-containing species on the chromatogram were integrated using Agilent
MassHunter software package. Since no peptide-based side products were generated in the
experiments, the yields shown in Table 2 were determined as follows: %yield = Spr/Stotal where
Spr is the peak area of the product and Stotal is the peak area of combined peptide-containing
species (product and starting material). For protein bioconjugation, deconvoluted masses of
proteins were obtained using maximum entropy algorithm. LC-MS data shown were acquired
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using Method A, unless otherwise noted. Mass spectrum insets correspond to the integration of
the TIC peak unless otherwise noted.
In addition to this method, reaction P3-1 was scaled up and subsequently purified via
mass-directed preparative HPLC and in order to determine isolated yield. The results of this
isolation can be found on page S24 under the subheading Large Scale Bioconjugation.
Synthesis of Oxidative Addition Complexes
Synthesis of [(1,5-COD)Pd(CH 2TMS)2j. A flame-dried Schlenk flask (100 mL), equipped with
a magnetic stir bar, was filled with argon and charged with (1,5-COD)PdCl 2 (3.15g, 11.05 mmol)
made according to literature reports.' The flask was put under vacuum and backfilled with argon
(the procedure was repeated 3 consecutive times). Diethyl ether (49.3 mL) was added via
syringe, the reaction was cooled to -40 'C (acetonitrile/dry ice bath) and TMSCH2MgCl (23.4
mL, 1.0 M) purchased from Sigma-Aldrich was added dropwise over 10-20 min. The reaction
mixture was stirred at -40 'C for 1 h and then at 0 'C (ice/water bath) for an additional 20 min.
Acetone (1.3 mL) was added at 0 'C, the reaction mixture was stirred for 5 min, after which time
the solvent was removed under vacuum using an external trap (the flask was kept at 0 'C). The
flask was then opened to air, pentane (100 mL) was added and the crude material was filtered
through a pad of Celite into a new round-bottom flask (500 mL) at 0 'C. The filter cake was
washed with pentane (50 mL x 2). Pentane from the combined washes was removed with the aid
of a rotary evaporator at 0 'C (ice/water bath). The resulting white solid was dried under vacuum
for 2 h at 0 0C, and transferred into a 20 mL scintillation vial in the glovebox (3.00 g, 70%). The
IH and 13 C NMR spectra of the obtained material are identical to those reported in the literature.'
The title compound was stored in the glovebox at -20 'C.
General Procedure for the Synthesis of mono-Palladium Oxidative Addition Complexes.
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TMs sSPhos (1.1 equiv) PCy 2A THF MeQ OMe
X = OTt, CI, Br 1.1 equiv rt, 1 h NaO 3S OA-Y
1 equiv (sSPhos)Pd(X)Ar
In a scintillation vial (10 mL) open to the air and equipped with a magnetic stir bar, the
vial was charged with ligand (1.1 equiv), Ar-X (1 equiv), and THF (1 mL). Solid (1,5-
COD)Pd(CH 2SiMe3)2 (1.1 equiv) was added rapidly in one portion and the resulting solution was
stirred for 1 h at rt. After this time, pentane (3 mL) was added and the resulting mixture was
capped and placed into a -20 'C freezer for 2 h. The vial was removed from the freezer and the
resulting precipitate was filtered, washed with pentane (5 x 3 mL), and dried under reduced
pressure to afford the oxidative addition complex.
PCy 2
IPr Nr Me
C1
OA-1
Following the general procedure, a mixture containing 4-chlorotoluene (6.4 pL, 0.054 mmol),
RuPhos (28 mg, 0.06 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (25 mg, 0.06 mmol) was stirred at rt
in a nitrogen-filled glovebox in cyclohexane (1.5 mL) for 18 h. The vial was removed from the
glovebox, opened to the air, and general work-up afforded OA-1 as a grey solid (37 mg, 96%).
The 'H and 1 3C NMR spectra of the obtained material are identical to those reported in the
literature.'
PCy 2
MeO omeOAMe
C1
OA-2
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Following the general procedure, a mixture containing 4-chlorotoluene (6.4 pL, 0.054 mmol),
SPhos (24.6 mg, 0.06 mmol), and (l,5-COD)Pd(CH 2TMS) 2 (25 mg, 0.06 mmol) was stirred at rt
in a nitrogen-filled glovebox in cyclohexane (1.5 mL) for 18 h. General work-up afforded OA-2
as a white solid (33 mg, 93%). The 'H and 13C NMR spectra of the obtained material are
identical to those reported in the literature.'
HRMS electrospray (m/z): [M - C1]* calcd for C33H42CIO2PPd: 607.1969, found 607.1962.
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Following the general procedure, a mixture containing 4-chlorotoluene (6.4 pL, 0.054 mmol),
sSPhos (33 mg, 0.06 mmol), and (l,5-COD)Pd(CH 2TMS) 2 (25 mg, 0.06 mmol) was stirred at rt
in THF (1 mL) for 1 h. General work-up afforded OA-3 as a yellow solid (41 mg, 99%).
'H NMR (400 MHz, MeOD) Complicated spectrum; please see the attached 'H NMR spectrum.
13C NMR (101 MHz, MeOD) d 161.39, 161.35, 157.73, 157.61, 139.18, 138.45, 138.38, 138.05,
135.46, 135.37, 135.19, 134.96, 134.89, 134.04, 133.08, 132.63, 132.49, 132.25, 132.02, 131.99,
131.80, 131.22, 130.20, 130.01, 129.50, 129.39, 129.09, 128.98, 128.54, 128.43, 126.96, 126.92,
126.90, 107.08, 107.02, 69.14, 64.04, 62.36, 61.71, 57.04, 56.68, 49.94, 49.73, 49.51, 49.30,
49.09, 48.88, 48.66, 39.00, 38.55, 38.35, 37.90, 35.49, 31.49, 29.24, 28.73, 28.69, 28.00, 27.96,
27.91, 27.83, 27.78, 27.70, 27.51, 27.44, 27.39, 27.34, 27.31, 27.14, 26.85, 26.82, 26.78, 26.58,
26.39, 25.92, 21.79, 20.98. (observed complexity is due to C-P coupling). 3 1P NMR (121 MHz,
MeOD) d 52.85. FT-IR (neat, cm'): 3438.12, 2929.53, 2849.99, 1570.73, 1438.17, 1395.08,
1275.77, 1229.37, 1176.35, 1106.75, 1083.55, 1053.72, 1017.27, 914.53, 894.65, 851.56, 815.11,
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762.08, 702.43, 665.97, 652.71. HRMS electrospray (m/z): [M - C1J calcd for
C33H41CNaO5PPdS: 709.1345, found 709.1337.
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Following the general procedure, a mixture containing fluorescein
monotrifluoromethanesulfonate (30 mg, 0.054 mmol), sSPhos (33 mg, 0.06 mmol), and (1,5-
COD)Pd(CH 2TMS) 2 (25 mg, 0.06 mmol) was stirred at rt in THF (1 mL) for 1 h. General work-
up afforded OA-20 as a red solid (54 mg, 94%).
'H NMR (400 MHz, MeOD) Complicated spectrum; please see the attached 'H NMR spectrum.
'
3C NMR (101 MHz, CD2 Cl2 ) d 171.22, 161.31, 157.55, 153.75, 153.62, 151.81, 150.75,
138.53, 138.46, 137.21, 135.48, 135.38, 134.85, 134.78, 134.18, 132.94, 132.46, 132.01, 131.99,
131.83, 131.72, 131.63, 131.16, 130.42, 128.53, 128.43, 127.93, 126.88, 126.86, 125.50, 123.61,
121.96, 121.68, 120.45, 118.78, 118.27, 111.88, 110.86, 108.61, 107.06, 104.01, 62.35, 57.39,
57.01, 56.66, 49.94, 49.73, 49.51, 49.30, 49.09, 48.88, 48.66, 39.02, 38.39, 38.36, 37.73, 35.86,
28.64, 28.61, 28.13, 27.86, 27.83, 27.78, 27.73, 27.66, 27.52, 27.48, 27.46, 27.39, 27.31, 27.26,
27.23, 27.11, 26.81, 26.77. (observed complexity is due to C-P coupling). 3 P NMR (121 MHz,
MeOD) d 55.32. FT-IR (neat, cm-1): 2939.44, 2365.12, 2334.10, 2229.64, 2193.02, 2171.53,
2162.71, 2154.39, 2030.18, 2020.55, 1768.04, 1578.01, 1451.18, 1425.24, 1400.41, 1295.66,
1257.24, 1224.09, 1172.18, 1100.84, 1052.69, 1019.40, 990.73, 848.30, 759.20, 652.11, 596.38.
HRMS electrospray (m/z): [M - OTfJ calcd for C4 7H4 5F3NaO12PPdS2: 933.1468, found
933.1496.
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Following the general procedure, a mixture containing aryl bromide (biotin) (30 mg, 0.054
mmol), sSPhos (33 mg, 0.06 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (25 mg, 0.06 mmol) was
stirred at rt in THF (1 mL) for 1 h. General work-up afforded OA-21 as a pink solid (54 mg,
99%).
'H NMR (400 MHz, MeOD) Complicated spectrum; please see the attached 'H NMR spectrum.
"C NMR (101 MHz, CD2C1 2) d 161.36, 161.36, 157.63, 138.35, 135.44, 134.98, 133.14,
133.02, 132.73, 131.99, 131.25, 128.54, 128.44, 126.93, 123.13, 107.07, 62.37, 56.68, 49.94,
49.72, 49.51, 49.30, 49.09, 48.88, 48.85, 48.66, 38.96, 38.69, 38.31, 28.75, 28.07, 27.70, 27.50,
27.37, 27.12, 26.85. (observed complexity is due to C-P coupling). 31P NMR (121 MHz,
MeOD) d 53.89. FT-IR (neat, cm-'): 3282.15, 2919.10, 2851.48, 1688.19, 1586.10, 1521.18,
1586.10, 1488.30, 1451.98, 1395.17, 1275.99, 1226.01, 1185.10, 1099.39, 1049.20, 1007.70,
853.33, 815.64, 764.68, 688.85, 677.29, 667.72, 648.10, 595.07. HRMS electrospray (m/z): [M
- Brj calcd for C42H54BrN3NaO7PPdS2 : 936.2085, found 936.2087.
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Following the general procedure, a mixture containing 4-chlorobenzaldehyde (8.4 mg, 0.054
mmol), sSPhos (31 mg, 0.06 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (25 mg, 0.06 mmol) was
stirred at rt in THF (1 mL) for 1 h. General work-up afforded OA-22 as a white solid (36 mg,
89%).
'H NMR (400 MHz, MeOD) Complicated spectrum; please see the attached 'H NMR spectrum.
3C NMR (101 MHz, CD2C 2) d 161.29, 157.50, 135.52, 135.42, 134.71, 132.77, 132.07,
131.10, 128.57, 128.47, 126.83, 107.07, 69.12, 62.34, 57.51, 56.69, 49.94, 49.73, 49.51, 49.30,
49.09, 48.87, 48.66, 39.06, 38.41, 38.18, 37.52, 35.84, 35.44, 29.23, 27.84, 27.70, 27.66, 27.46,
27.35, 27.13, 26.76, 23.64, 14.68, -1.12. (observed complexity is due to C-P coupling). 31P
NMR (121 MHz, MeOD) d 55.14. FT-IR (neat, cm-): 3501.12, 2928.70, 2849.99, 2361.49,
2344.31, 1690.19, 1571.43, 1550.27, 1450.50, 1398.96, 1211.92, 1098.84, 1050.83, 1008.78,
834.27, 808.78, 759.26, 693.54, 667.90, 662.51, 639.86, 590.44. HRMS electrospray (m/z): [M
- Br]* calcd for C33H39BrNaO6PPdS: 723.1148, found 723.1158.
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Following the general procedure, a mixture containing 4-bromophenylacetylene (9.7 mg, 0.054
mmol), sSPhos (31 mg, 0.06 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (25 mg, 0.06 mmol) was
stirred at rt in THF (1 mL) for 1 h. General work-up afforded OA-23 as a yellow solid (36 mg,
89%).
'H NMR (400 MHz, MeOD) Complicated spectrum; please see the attached 'H NMR spectrum.
'
3 C NMR (101 MHz, MeOD d 161.54, 157.79, 138.72, 138.65, 135.69, 135.60, 135.11, 135.04,
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133.22, 132.74, 132.24, 132.22, 131.91, 131.40, 128.76, 128.66, 127.10, 107.29, 69.35, 62.57,
56.89, 50.15, 49.94, 49.73, 49.51, 49.30, 49.09, 48.87, 43.15, 39.23, 38.66, 38.58, 38.01, 28.90,
28.71, 28.10, 28.03, 27.97, 27.90, 27.71, 27.67, 27.61, 27.35, 27.05, 27.01, 26.99. (observed
complexity is due to C-P coupling). 31 P NMR (121 MHz, MeOD) d 58.96. FT-IR (neat, cm'1):
3430.11, 3200.11, 2929.69, 2852.02, 1247071, 2339.26, 1572.29, 1450.85, 1398.15, 1228.42,
1098.54, 1050.80, 1009.71, 916.01, 849.38, 812.33, 759.15, 693.48, 667.86, 656.56, 585.72
HRMS electrospray (m/z): [M - Brj calcd for C34H39BrNaO 5PPdS: 719.1199, found
719.1217.
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Following the general procedure, a mixture containing 4-chloroquinoline (9.8 mg, 0.054 mmol),
sSPhos (31 mg, 0.06 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (25 mg, 0.06 mmol) was stirred at rt
in THF (1 mL) for 1 h. General work-up afforded OA-24 as a light brown solid (40 mg, 94%).
1H NMR (400 MHz, MeOD) Complicated spectrum; please see the attached 'H NMR spectrum.
13C NMR (101 MHz, MeOD) d 161.56, 157.82, 138.59, 135.68, 135.58, 135.18, 135.11, 133.28,
132.83, 132.21, 132.00, 131.43, 128.76, 128.65, 127.13, 107.29, 69.35, 62.58, 56.89, 50.15,
49.94, 49.73, 49.51, 49.30, 49.09, 48.88, 39.21, 38.76, 38.56, 38.10, 36.10, 35.81, 28.91, 28.17,
28.11, 28.04, 27.98, 27.90, 27.72, 27.52, 27.35, 27.03, 26.99, 23.88, 14.88 (observed complexity
is due to C-P coupling). 31P NMR (121 MHz, MeOD) d 52.73. FT-IR (neat, cm~'): 3418.60,
2928.65, 2849.95, 2360.04, 2339.28, 1572.13, 1495.74, 1450.01, 1398.16, 1367.97, 1280.36,
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1189.32, 1097.91, 1049.60, 915.43, 813.53, 693.38, 635.12, 594.93. HRMS electrospray (m/z):
[M - Cl]* calcd for C35H40ClNNaO 5PPdS: 746.1308, found 746.1310.
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Following the general procedure, a mixture containing 1-Bromo-3,5-difluorobenzene (9.8 mg,
0.054 mmol), sSPhos (31 mg, 0.06 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (25 mg, 0.06 mmol)
was stirred at rt in THF (1 mL) for 1 h. General work-up afforded OA-25 as a yellow solid (45
mg, 99%).
H NMR (400 MHz, MeOD) Complicated spectrum; please see the attached 'H NMR spectrum.
3C NMR (101 MHz, MeOD) d 163.75, 161.83, 161.35, 160.11, 158.07, 157.60, 155.19, 138.44,
138.36, 136.21, 135.48, 135.38, 134.96, 134.88, 133.03, 132.89, 132.57, 132.04, 132.01, 131.91,
131.74, 131.21, 130.32, 129.10, 128.56, 128.46, 127.24, 126.91, 126.89, 112.56, 112.49, 112.38,
112.31, 108.10, 107.07, 105.09, 104.83, 104.58, 69.15, 62.43, 62.36, 61.71, 56.86, 56.68, 49.94,
49.73, 49.51, 49.30, 49.09, 48.87, 48.66, 40.13, 38.99, 38.52, 38.34, 37.87, 32.17, 28.72, 27.98,
27.90, 27.82, 27.77, 27.69, 27.51, 27.44, 27.39, 27.31, 27.13, 26.84, 26.79, 9.92, 0.26, -1.91
(observed complexity is due to C-P coupling). 31P NMR (121 MHz, MeOD) d 52.68. FT-IR
(neat, cm1): 3390.01, 2931.31, 2849.99, 2362.81, 2344.29, 1597.25, 1577.36, 1448.11, 1398.96,
1227.38, 1182.98, 1100.89, 1023.90, 997.38, 968.81, 924.47, 897.96, 840.21, 808.48, 759.58,
699.11, 662.66, 590.27. HRMS electrospray (m/z): [M - Brj calcd for
C32H37BrF2NaO 5PPdS: 731.1010, found 731.1020.
General Procedure for the Synthesis of mono-Palladium Oxidative Addition Complexes.
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- TMS sSPhos (2.2 equiv) PCy2
A + O TMS THF MeO MOO
X = CI, Br 2.2 equiv rt, 1 h 
_NaO 3 S J2 OA-Y
[(sSPhos)Pd(X)] 2Ar
A scintillation vial (10 mL), equipped with a magnetic stir bar, was charged with sSPhos
(2.2 equiv), Ar-X (1 equiv), and THF (1.5 mL). Solid (1,5-COD)Pd(CH2SiMe3)2 (2.2 equiv) was
added rapidly in one portion and the resulting solution was stirred for 1 h at rt. After this time,
pentane (3 mL) was added and the resulting mixture was placed into a -20 'C freezer for 2 h.
The vial was removed from the freezer and, in the air, the resulting precipitate was filtered,
washed with pentane (5 x 3 mL), and dried under reduced pressure to afford the oxidative
addition complex.
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Following the general procedure, a mixture containing 1,4-dibromobenzene (12.7 mg, 0.054
mmol), sSPhos (61 mg, 0.119 mmol), and (l,5-COD)Pd(CH 2TMS) 2 (46 mg, 0.119 mmol) was
stirred at rt in THF (1.5 mL) for 1 h. General work-up afforded OA-7 as a brown solid (76 mg,
96%).
'H NMR (400 MHz, MeOD) Complicated spectrum; please see the attached 'H NMR spectrum.
"C NMR (101 MHz, MeOD) d 161.33, 157.58, 135.48, 134.89, 134.82, 133.01, 132.02, 132.00,
131.18, 128.54, 128.44, 107.07, 69.14, 62.35, 56.68, 49.94, 49.73, 49.51, 49.30, 49.09, 48.87,
48.66, 39.02, 38.45, 38.37, 37.79, 27.89, 27.81, 27.76, 27.69, 27.50, 27.30, 27.14, 26.78, 2.88, -
1.91. (observed complexity is due to C-P coupling). 3 1P NMR (121 MHz, MeOD) d 50.93. FT-
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IR (neat, cm-'): 3440.34, 2919.59, 2849.99, 2372.76, 2154.02, 1646.96, 1574.05, 1458.05,
1441.48, 1395.08, 1275.77, 1226.06, 1176.35, 1159.78, 1100.12, 1053.72, 1010.64, 944.07,
914.53, 891.33, 851.66, 798.54, 758.77, 732.25, 692.48, 646.08. HRMS electrospray (m/z): [M
- NaBr2]* caled for C58H72Br2Na2O1 OP 2Pd2S 2: 1291.2038, found 1291.2011.
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Following the general procedure, a mixture containing 4,4-Dibromobiphenyl (16.8 mg, 0.054
mmol), sSPhos (61 mg, 0.119 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (46 mg, 0.119 mmol) was
stirred at rt in THF (1.5 mL) for I h. General work-up afforded OA-8 as a brown solid (81 mg,
96%).
'H NMR (400 MHz, MeOD) Complicated spectrum; please see the attached 'H NMR spectrum.
"C NMR (101 MHz, MeOD) d 161.31, 134.81, 132.90, 132.04, 131.59, 131.15, 129.59, 128.55,
128.45, 127.51, 107.07, 62.35, 57.08, 56.68, 49.94, 49.73, 49.51, 49.30, 49.09, 48.87, 48.66,
39.04, 38.39, 37.68, 35.58, 27.80, 27.74, 27.68, 27.48, 27.23, 27.13, 26.77, 23.66, 14.68, 2.95, -
1.43. (observed complexity is due to C-P coupling). 31P NMR (121 MHz, MeOD) d 50.65. FT-
IR (neat, cm~'): 3461.21, 2929.43, 2846.68, 2361.39, 2163.96, 1576.27, 1450.80, 1141.65,
1272.46, 1232.69, 1179.17, 1096.81, 1051.15, 998.40, 924.47, 888.02, 851.56, 802.14, 759.54,
662.66, 656.69, 639.46. HRMS electrospray (m/z): [M - NaBr2]* calcd for
C64H76Br2Na2OlOP 2Pd2 S2 : 1367.2354, found 1367.2304.
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Following the general procedure, a mixture containing 2,6-Dibromonaphthalene (12.7 mg, 0.044
mmol), sSPhos (50 mg, 0.01 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (38 mg, 0.01 mmol) was
stirred at rt in THF (1.5 mL) for 1 h. General work-up afforded OA-9 as a light red solid (63 mg,
94%).
'H NMR (400 MHz, MeOD) Complicated spectrum; please see the attached 'H NMR spectrum.
"C NMR (101 MHz, MeOD) d "C NMR (101 MHz, MeOD) 6 159.73, 159.65, 155.98, 155.88,
137.04, 136.97, 133.88, 133.79, 133.47, 133.08, 133.00, 131.18, 130.75, 130.64, 130.57, 130.41,
129.81, 129.47, 128.35, 127.45, 127.34, 126.92, 126.80, 125.28, 125.22, 125.20, 105.43, 105.40,
67.49, 60.71, 60.11, 55.87, 55.06, 55.05, 48.31, 48.09, 47.88, 47.67, 47.45, 47.24, 47.03, 37.44,
36.78, 36.54, 35.88, 34.21, 33.93, 26.91, 26.21, 26.15, 26.08, 26.03, 25.92, 25.83, 25.73, 25.50,
25.13, 22.01, 13.05, -1.36, -2.95, -3.05. (observed complexity is due to C-P coupling). 31P NMR
(121 MHz, MeOD) d 52.23. FT-IR (neat, cm-'): 3438.11, 2928.54, 2850.71, 2361.41, 2339.24,
2151.04, 1637.01, 1572.72, 1450.76, 1398.53, 1275.60, 1180.17, 1098.57, 1017.90, 917.07,
872.32, 845.66, 805.86, 758.91, 693.63, 667.85, 640.04, 554.21. HRMS electrospray (m/z): [M
- Na2Br]- calcd for C62H74Br2Na2OIoP2Pd2S2: 1397.1481, found 1397.1495.
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Following the general procedure, a mixture containing 2,8-dibromodibenzofuran (14.3 mg, 0.044
mmol), sSPhos (50 mg, 0.01 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (38 mg, 0.01 mmol) was
stirred at rt in THF (1.5 mL) for 1 h. General work-up afforded OA-10 as a brown solid (67.3
mg, 98%).
'H NMR (400 MHz, MeOD) Complicated spectrum; please see the attached 'H NMR spectrum.
"C NMR (101 MHz, MeOD) d 159.65, 155.90, 136.90, 136.83, 133.49, 131.28, 130.78, 130.44,
129.95, 129.62, 129.38, 128.46, 128.21, 125.22, 105.89, 104.94, 68.44, 67.97, 67.48, 55.77,
55.28, 54.77, 48.28, 48.18, 48.07, 47.86, 47.65, 47.43, 47.22, 47.01, 36.42, 25.76, 25.12, 22.01,
12.91. (observed complexity is due to C-P coupling). P NMR (121 MHz, MeOD) d 52.13.
FT-IR (neat, cm~'): 3431.09 2928.88, 2846.68, 2361.40 2339.29, 1576.61, 1450.75, 1398.27,
1275.76, 1184.90, 1098.21, 1184.90, 924.47, 891.33, 854.88, 805.64, 693.56, 618.24, 590.59.
HRMS electrospray (m/z): [M - NaBr2]* calcd for C64H74Br2Na2 O1IP2Pd2 S 2 : 1381.2146,
found 1381.2172.
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Following the general procedure, a mixture containing 3,5-Dibromophenol (11.2 mg, 0.044
mmol), sSPhos (50 mg, 0.01 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (38 mg, 0.01 mmol) was
stirred at rt in THF (1.5 mL) for 1 h. General work-up afforded OA-11 as a light red solid (55
mg, 86%).
'H NMR (400 MHz, MeOD) Complicated spectrum; please see the attached 'H NMR spectrum.
13 C NMR (101 MHz, MeOD) d 161.14, 157.39, 138.12, 135.25, 135.16, 134.77, 134.70, 132.84,
132.39, 131.82, 131.56, 131.00, 128.35, 128.25, 126.69, 123.78, 106.86, 68.93, 62.15, 56.47,
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49.73, 49.51, 49.30, 49.09, 48.87, 48.66, 48.45, 38.76, 38.35, 38.11, 37.69, 28.50, 27.77, 27.69,
27.61, 27.56, 27.48, 27.29, 27.09, 26.92, 26.63, 26.58, 23.48, 14.48 (observed complexity is due
to C-P coupling). 31P NMR (121 MHz, MeOD) d 54.69. FT-IR (neat, cm-'): 3439.91, 2929.07,
2851.92, 2360.02, 2339.23, 1572.55, 1495.89, 1449.24, 1398.44, 1275.67, 1180.53, 1097.678,
1049.39, 1017.65, 915.80, 890.18, 813.09, 758.97, 731.45, 693.45, 667.85, 639.68, 599.38.
HRMS electrospray (m/z): [M - Na 2Br] calcd for C5 8H7 2Br2Na 2OlP2Pd2 S2 : 1363.1273,
found 1363.1279.
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Following the general procedure, a mixture containing 3,5-Dibromoaniline (11.2 mg, 0.044
mmol), sSPhos (50 mg, 0.01 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (38 mg, 0.01 mmol) was
stirred at rt in THF (1.5 mL) for 1 h. General work-up afforded OA-12 as a brown solid (68 mg,
99%).
1H NMR (400 MHz, MeOD) Complicated spectrum; please see the attached 'H NMR spectrum.
'
3C NMR (101 MHz, MeOD) d 159.68, 155.91, 133.82, 133.26, 133.18, 131.32, 130.37, 129.52,
126.89, 126.79, 125.23, 105.41, 67.47, 60.69, 55.01, 48.27, 48.06, 47.84, 47.63, 47.42, 47.20,
46.99, 37.32, 36.79, 36.67, 36.14, 33.93, 27.04, 27.00, 26.14, 26.09, 26.01, 25.77, 25.72, 25.63,
25.46, 25.11, 22.01, 13.02 (observed complexity is due to C-P coupling) .3P NMR (121 MHz,
MeOD) d 54.64. FT-IR (neat, cm~'): 3438.02, 2929.17, 2850.03, 2360.11, 2344.27, 2156.91,
1576.54, 1450.55, 1400.19, 1275.83, 1226.92, 1179.84, 1098.40, 1051.05, 1017.72, 916.95,
889.51, 852.34, 815.45, 763.84, 693.63, 630.54, 575.96. HRMS electrospray (m/z): [M -
Na2BrJ- caled for C58H73Br2NNa 2OIOP2Pd2S 2: 1362.1432, found 1362.1460.
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Following the general procedure, a mixture containing 3,5-Dibromopyridine (10.5 mg, 0.044
mmol), sSPhos (50 mg, 0.01 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (38 mg, 0.01 mmol) was
stirred at rt in THF (1.5 mL) for 1 h. General work-up afforded OA-13 as a brown solid (65 mg,
99%).
'H NMR (400 MHz, MeOD) Complicated spectrum; please see the attached 'H NMR spectrum.
'
3C NMR (101 MHz, MeOD) d 161.30, 160.89, 157.93, 157.52, 138.70, 135.53, 135.44, 134.73,
134.65, 132.83, 132.30, 132.05, 131.11, 128.55, 128.45, 126.87, 119.94, 107.78, 107.08, 72.31,
69.13, 62.34, 62.15, 57.47, 56.68, 49.94, 49.73, 49.51, 49.30, 49.09, 48.88, 48.66, 39.08, 38.42,
38.18, 37.52, 35.86, 35.57, 35.45, 31.55, 28.54, 27.71, 27.56, 27.47, 27.36, 26.77, 26.74, 26.58,
25.28, 23.65, 14.67 (observed complexity is due to C-P coupling). 31P NMR (121 MHz, MeOD)
d 52.54. FT-IR (neat, cm-'): 3431.02, 2928.78, 2849.99, 2361.41, 2339.26, 1575.57, 1514.39,
1450.71, 1398.62, 1275.14, 1179.98, 1098.18, 1049.74, 1017.55, 916.89, 808.43, 748.89, 693.58,
667.83, 656.40, 629.29, 623.44, 618.19, 613.58, 608.38, 585.53. HRMS electrospray (m/z): [M
- Na2Br]~ caled for C57H71Br2NNa 2O1OP2Pd2S 2: 1348.1276, found 1348.1303.
OMePCy 2  OMe
MeO
NaO 3S Br MeO Br
OA-14
111
Following the general procedure, a mixture containing 1,4-Dibromo-2,5-dimethoxybenzene
(13.1 mg, 0.044 mmol), sSPhos (50 mg, 0.01 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (38 mg, 0.01
mmol) was stirred at rt in THF (1.5 mL) for 1 h. General work-up afforded OA-14 as a brown
solid (56 mg, 84%).
'H NMR (400 MHz, MeOD) Complicated spectrum; please see the attached 'H NMR spectrum.
"C NMR (101 MHz, MeOD) d 161.28, 157.50, 155.77, 151.98, 138.70, 138.63, 135.53, 135.43,
134.70, 133.38, 132.79, 132.23, 132.07, 131.40, 131.08, 128.56, 128.46, 126.84, 120.35, 115.84,
114.53, 113.05, 107.07, 106.50, 69.12, 62.33, 57.59, 57.52, 56.70, 56.66, 56.42, 56.15, 49.94,
49.73, 49.51, 49.30, 49.09, 48.87, 48.66, 39.07, 38.41, 38.11, 37.46, 35.84, 35.56, 35.44, 27.84,
27.77, 27.65, 27.45, 27.35, 27.13, 26.76, 26.73, 26.56, 25.27, 23.64, 14.67, -1.17 (observed
complexity is due to C-P coupling). 3 1P NMR (121 MHz, MeOD) d 52.47. FT-IR (neat, cm~ 1):
3438.09, 2928.62, 2850.33, 2362.65, 2342.57, 1572.78, 1450.63, 1398.55, 1274.73, 1179.23,
1097.97, 1050.91, 1018.53, 917.05, 889.44, 845.20, 805.62, 758.86, 693.43, 667.84, 656.47,
630.17, 623.71, 618.06, 580.82. HRMS electrospray (m/z): [M - Na2Br] caled for
C6oH76Br2 Na2O1 2P2Pd2S 2: 1407.1536, found 1407.1493.
H
P y fC\- N
W~eIMeO -sSPhos
I, BrNaO 30SB Br
OA-15
Following the general procedure, a mixture containing Bis(4-bromophenyl)amine (14.5 mg,
0.044 mmol), sSPhos (50 mg, 0.01 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (38 mg, 0.01 mmol)
was stirred at rt in tetrahydrofuran (1.5 mL) for 1 h. General work-up afforded OA-15 as a
brown solid (61 mg, 90%).
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'H NMR (400 MHz, MeOD) Complicated spectrum; please see the attached 'H NMR spectrum.
"C NMR (101 MHz, MeOD) d 161.58, 161.51, 157.74, 145.69, 138.81, 138.73, 135.72, 135.62,
135.00, 134.92, 133.08, 132.54, 132.43, 132.27, 131.71, 131.34, 130.86, 130.46, 130.19, 129.31,
129.19, 128.77, 128.67, 127.07, 127.04, 122.28, 121.54, 120.15, 118.77, 107.28, 107.23, 69.34,
62.55, 61.93, 56.90, 50.15, 49.94, 49.72, 49.51, 49.30, 49.08, 48.87, 39.24, 38.59, 38.46, 37.80,
36.05, 35.79, 28.07, 27.99, 27.94, 27.87, 27.75, 27.68, 27.62, 27.55, 27.34, 26.99, 26.95, 26.78,
23.88, 14.90, -0.62, -1.26. 31P NMR (121 MHz, MeOD) d 51.29. FT-IR (neat, cm'1): 3433.28,
2929.21, 2849.91, 2361.32, 2339.25, 1576.44, 1549.56, 1527.65, 1449.33, 1398.11, 1275.60,
1180.69, 1098.13, 1049.70, 1017.93, 915.75, 888.02, 848.40, 758.90, 693.55, 559.72. HRMS
electrospray (m/z): [M - Na 2Brj- calcd for C64H77Br2NNa 2OIoP2Pd2S2: 1438.1717, found
1438.1705.
OPCy2 S
MeO M sSPhos
NaO3S Br Br
OA-16
Following the general procedure, a mixture containing 3,4-Dibromothiophene (5 piL, 0.044
mmol), sSPhos (50 mg, 0.01 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (38 mg, 0.01 mmol) was
stirred at rt in THF (1.5 mL) for 1 h. General work-up afforded OA-16 as a brown solid (57 mg,
89%).
'H NMR (400 MHz, MeOD) Complicated spectrum; please see the attached 'H NMR spectrum.
13C NMR (101 MHz, MeOD) d "C NMR (101 MHz, MeOD) 6 161.67, 161.44, 161.28, 157.49,
135.54, 135.44, 134.67, 134.59, 133.84, 132.78, 132.06, 132.04, 131.39, 131.08, 129.79, 128.56,
128.45, 126.85, 124.69, 107.07, 104.95, 69.12, 63.94, 62.70, 62.33, 57.23, 56.69, 49.94, 49.73,
49.51, 49.30, 49.09, 48.87, 48.66, 39.08, 38.43, 38.10, 37.44, 32.32, 29.30, 29.18, 28.53, 27.84,
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27.78, 27.71, 27.65, 27.46, 27.13, 26.77, 26.73, 2.91, 2.50, 2.45, 0.50 (observed complexity is
due to C-P coupling). 3 1P NMR (121 MHz, MeOD) d 52.49. FT-IR (neat, cm~'): 3391.02,
2928.68, 2852.01, 2360.05, 2339.30, 1576.87, 1450.45, 1399.99, 1274.77, 1226.06, 1179.26,
1098.10, 1051.00, 1017.61, 917.42, 889.34, 852.10, 763.72, 693.50, 667.84, 590.39. HRMS
electrospray (m/z): [M - Na]* caled for C56H7oBr2Na2OloP2Pd2S3: 1456.9946, found
1456.9976.
HO
PCy 2OMe
MeO - P
/a)3 Br "/SSPhosNaO3S / B
OA-17 Br
Following the general procedure, a mixture containing 3,5-Dibromobenzoic acid (12.3 mg, 0.044
mmol), sSPhos (50 mg, 0.01 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (38 mg, 0.01 mmol) was
stirred at rt in THF (1.5 mL) for 1 h. General work-up afforded OA-17 as a light brown solid (72
mg, 99%).
'H NMR (400 MHz, MeOD) Complicated spectrum; please see the attached 'H NMR spectrum.
'
3C NMR (101 MHz, MeOD) d 161.49, 157.72, 143.63, 138.87, 138.80, 136.63, 135.72, 135.62,
134.94, 134.86, 133.51, 133.04, 132.86, 132.51, 132.24, 132.22, 131.68, 131.31, 130.11, 128.76,
128.65, 128.20, 127.06, 127.04, 123.76, 121.57, 108.72, 107.27, 69.33, 63.76, 62.54, 57.67,
57.27, 57.12, 56.88, 56.58, 39.27, 38.62, 38.40, 37.74, 36.06, 35.77, 29.43, 28.94, 28.78, 28.53,
28.41, 28.05, 27.99, 27.93, 27.85, 27.76, 27.68, 27.56, 27.40, 27.34, 26.97, 26.94, 23.85, 14.89,
3.26, -0.62. 31P NMR (121 MHz, MeOD) d 31.99. FT-IR (neat, cm1): 3436.31, 2928.88,
2846.68, 2361.40, 2339.29, 1576.61, 1450.75, 1398.27, 1275.76, 1184.90, 1098.21, 1049.48,
1018.42, 924.47, 891.33, 854.88, 805.64, 749.56, 693.56, 580.79. HRMS electrospray (m/z):
[M - Na 2Brj caled for C59H72Br2Na2O1 2P2Pd2S2: 1391.1222, found 1391.1283.
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MeO \/
, A Br sSPhos
NaO 3S
OA-18 Br
Following the general procedure, a mixture containing 3,5-Dibromobenzaldehyde (11.6 mg,
0.044 mmol), sSPhos (50 mg, 0.01 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (38 mg, 0.01 mmol)
was stirred at rt in THF (1.5 mL) for 1 h. General work-up afforded OA-18 as a light brown solid
(66 mg, 99%).
'H NMR (400 MHz, MeOD) Complicated spectrum; please see the attached 'H NMR spectrum.
3C NMR (101 MHz, MeOD) d 161.29, 157.50, 135.52, 135.42, 134.71, 132.77, 132.07, 131.10,
128.57, 128.47, 126.83, 107.07, 69.12, 62.34, 57.51, 56.69, 39.06, 38.41, 38.18, 37.52, 35.84,
35.44, 29.23, 27.84, 27.70, 27.66, 27.46, 27.35, 27.13, 26.76, 23.64, 14.68, -1.12 (observed
complexity is due to C-P coupling). 3 1P NMR (121 MHz, MeOD) d 54.11. FT-IR (neat, cm~'):
3430.23, 2931.05, 2852.56, 2361.33, 2342.60, 1573.87, 1450.86, 1398.46, 1275.65, 1179.90,
1098.08, 1050.93, 1018.24, 917.08, 845.59, 805.57, 758.75, 693.59, 667.86, 657.88, 629.64,
623.64, 595.12. HRMS electrospray (m/z): [M - Na2Brj caled for C5qH72Br2Na2 O1 IP2 Pd2S 2 :
1375.1273, found 1375.1321.
PCy 2OMe
MeO e
NaO 3 I Br sSPhos
Br
OA-19
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Following the general procedure, a mixture containing 5,11-
dibromotricyclo[8.2.2.2~4,7~]hexadeca-1(12),4,6,10,13,15-hexaene (16.1 mg, 0.044 mmol),
sSPhos (50 mg, 0.01 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (38 mg, 0.01 mmol) was stirred at rt
in THF (1.5 mL) for 1 h. General work-up afforded OA-19 as a yellow solid (70 mg, 99%).
'H NMR (400 MHz, MeOD) Complicated spectrum; please see the attached 'H NMR spectrum.
"C NMR (101 MHz, MeOD) d 13 C NMR (101 MHz, MeOD) 6 161.28, 157.50, 138.66, 137.19,
135.54, 135.44, 134.67, 134.60, 132.79, 132.05, 131.08, 128.57, 128.47, 126.84, 107.07, 69.13,
62.34, 57.21, 56.69, 49.94, 49.73, 49.51, 49.30, 49.09, 48.87, 48.66, 39.09, 38.44, 38.11, 37.45,
36.89, 27.85, 27.79, 27.67, 27.57, 27.46, 27.38, 27.14, 26.77, 23.65, 14.68 (observed complexity
is due to C-P coupling). 3 1 P NMR (121 MHz, MeOD) d 51.64. FT-IR (neat, cm-1): 3300.18,
2918.84, 2851.36, 2358.93, 1684.54, 1577.43, 1525.12, 1450.92, 1274.75, 1226.24, 1185.07,
1098.68, 1050.30, 1017.95, 914.53, 852.15, 818.16, 759.53, 707.02, 693.31, 667.99, 596.57.
HRMS electrospray (m/z): [M - Na 2Br]~ calcd for C68H82Br2Na2OIOP2Pd2S 2: 1477.2109,
found 1477.2068.
Linear Peptide Synthesis
General Linear Peptide Synthesis Procedure:
All peptides were synthesized on a 0.2 mmol scale using manual Fmoc-SPPS chemistry under
flow with a 3 min cycle for each amino acid.2 Specifically, all reagents and solvents were
delivered to a stainless steel reactor containing resins at a constant flow rate using HPLC pump;
the temperature of the reactor was maintained at 60 'C during the synthesis using a water bath.
The procedure for each amino acid coupling cycle included: 1) a 30 s coupling with 1 mmol of
the corresponding Fmoc-protected amino acid, 1 mmol HBTU, and 500 pL of diisopropyl ethyl
amine (DIPEA) in 2.5 mL of DMF at a flow rate of 6 mL/min (note that for the coupling of
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cysteine and tryptophan, 190 pL of DIPEA was used to prevent racemization); 2) 1 min wash
with DMF at a flow rate of 20 mL/min; 3) 20 s deprotection with 50% (v/v) piperidine in DMF
at a flow rate of 20 mL/min; and 4) 1 min wash with DMF at a flow rate of 20 mL/min. After
completion of the stepwise SPPS, the resin was washed thoroughly with CH2Cl 2 and dried under
vacuum. The peptide was simultaneously cleaved from the resin and deprotected on the side-
chains by treatment with 2.5% (v/v) water, 2.5% (v/v) 1,2-ethanedithiol (EDT), and 2.5% (v/v)
triisoproprylsilane in neat trifluoroacetic acid (TFA) for 7 min at 60 'C. The resulting solution
was then triturated and washed with cold diethyl ether (3x). The obtained solid was dissolved in
50% H20 : 50% acetonitrile containing 0.1% TFA and lyophilized. The following peptides were
synthesized following this procedure:
NH p 0 O SH 0 0NH 0 f H0O H 0  0
H 2N NN N--N N N N N N -f N H2
NH 2  0 HH 2 0 o o
P1
Arg Ser Asn Phe Phe Leu Gly Cys Ala Gly Ala
Exact Mass: 1140.55
H 2N NH
HO H
H SH OH
NH 2
P2
Ala Cys Tyr Lys Arg Ser Asp Phe Thr Cys Gly Gly Gly Ser
Exact Mass: 1449.61
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NH 2  HN NH 2
0 OH NH
OHO PHO H 0  H 0
N )N N N N N NH2H H H H 0  EHNH 2 H SH OH
HO 0
P3
Thr Asp GIu Tyr Cys Lys Ser Arg
Exact Mass: 999.44
Peptide Purification
Table S1. Sequences and masses of peptides synthesized by manual fast flow SPPS.
Calculated Observed
Peptide Sequencea
mass Mass [M+H]
P1 NH2-RSNFFLGCAGA-C(O)NH 2  1140.55 1141.55
P2 NH2-ACYKRSDFTCGGGS-C(O)NH 2  1449.61 1450.63
P3 NH2-TDGYCKSR-C(O)NH 2  999.44 1000.42
a Cysteine residues are highlighted in red.
P1:
[M+2H]2 +
571.28
1+[M+1H]
1141.55 I
600 1200
4 111
Acquisition Time (min)
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P2:
[M+2H] 2
725.82
800 1400
1 2 3 4 5 6 7 8 9 10 11
Acquisition Time (min)
P3:
[M+2H]
500.72
[M+1 H]1000.42
500 00
4 7 1b 11
Acquisition Time (min)
General Bioconiugation Procedure
A solution of the Pd reagent (OA-Y) reagent in water (40 mM) was added to a solution of
peptide P3 (20 mM) in Tris buffer (0.1 M, pH 7.5). Note: if the palladium reagent was not
readily soluble in H2 0, the slurry was sonicated for 10 s to facilitate this process and become
fully solubilized. Final conditions: [Pd] = 20 mM; [peptide] = 10 mM; After 5 min at rt, 3-
mercaptopropionic acid (3 equiv to the palladium complex, solution in 6 mL of H20) was added
to the reaction mixture to quench the remaining palladium species. The reaction was allowed to
stand for 5 min and subsequently characterized by LC-MS.
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SH
H2N- nroeted pp +
NH2  MaO
P3: NH 2-TDEYCKSR-C(O)NH 2  NaO3SExact Mass: 999.44
10 pM
Crude Reaction Mixture
S
01 ~ ~ ' H.. .
0 H H NH
Br
OA-21
20 iM
3+
[M+31-1
439.86
-LtL 2+
4C
[M+2H]
659.29
0 600
P3-1
Product
0 0
HN H
TRIS buffer SN H
(pH 7.5, 0.1 M),
H2 0
5 min, rt S
quench with 03-thiopropionic acid H2N unprotected pep
NH2
Exact Mass: 1316.56
P3-1
Pd-species
decomposition
bv-products
1 2 3 4 5 6 7 8 9 10 11
Acquisition Time (min) Pd-species
decomposition
by-products
Control reaction
without peptide
1 2 3 4
SH
H 2N unprotected peptid+
NH 2
P3: NH2-TDEYCKSR-C(O)NH 2Exact Mass: 999.44
10 JAM
5 6 7
Acquisition Time (min) 8 9 10 11
0 H
TRIS buffer
PCY2  (pH 7.5, 0.1 M),
- OMe H20 S
MeH 5 min, rt 0
NaO3S Br quench with H2N unprotected peptld3-thiopropionic acid NH 2OA-22
20 siM
Exact Mass: 1103.47
P3-2
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3+
[M+3H]
368.83 Pd-species
2+
[M+2H] decomposition
562.74 by-products
P3-2
Product
400 600
reLCrude Reaction Mixtu
2 3 4 5 6 7 8 9 10 11
Acquisition Time (min) Pd-species
decomposition
by-products
Control reaction
without peptide
1 2 3 4 5 6 7 8 9 10 11
Acquisition Time (min)
SH TRIS buffer
O PCy2  (pH 7.5, 0.1 M),H2 N H20 __H2~nroecdpape + OMe _ 2
NH 2  MeO - -- m , r5 min, rt 0
NaO S B quench with H2N unprotected pep:UdeP3: NH 2-TDEYCKSR-C(O)NH 2  3-thiopropionic acid NH 2
Exact Mass: 999.44 OA-23 Exact Mass: 1099.48
10 IM 20 pM P3-3
3+
M+3H] Pd-species
P3-3 decomposition
M2+ Pdutby-products
Crude Reaction Mixture 550.74
400 600
2610 11
Acquisition Time (min) Pd-species
decomposition
by-products
Control reaction
without peptide
1 2 3 4 5 6 7
Acquisition Time (min) 8 9 10 11
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rSH
H 2N unprotected p
P3: NH 2-TDEYCKSR-C(O)NH 2Exact Mass: 999.44
10 AM
/PCy 2 _+ OMe 2
MeO --- N
Naa Br
NaO3S
OA-24
20 RM
3+[M+3H]
376.50
[M+
564
400 6Mixture
2+ 02A
TRIS buffer
(pH 7.5, 0.1 M),
H20
5 min, rt
quench with H2N unprotected
3-thiopropionic acid NH2
Exact Mass: 1126.48
P3-4
Pd-species
decomposition
4 5 6 7 8 9 10 11
Acquisition Time (min)
Pd-species
decomposition
Control reaction by-products
without peptide
1 2 3 4 5 6 7
Acquisition Time (min) 8 9 10 11
SH
H 2N unprotected peptide
NH2
P3: NH 2-TDEYCKSR-C(O)NH 2Exact Mass: 999.44
10 [LM
I PCy F
+ IOMe A2MeO ----
NaO3S Br F
OA-25
20 jiM
TRIS buffer
(pH 7.5, 0.1 M),
H20 S
5 min, rt 0
quench with H2N unprotected peptide-3-thiopropionic acid NH 2
Exact Mass: 1111.45
P3-5
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Crude Reaction
2 Product by-products
.0
-
3+
37.48 P3-5 Pd-species
[M+2H] Product decomposition
556.72 by-products
Crude Reaction MixtureI
400 600
1 2 4 5 6 7 9 1 11
Acquisition Time (min) Pd-species
decomposition
by-products
Control reaction
without peptide
1 2 3 4 5 6 7 8 9 10 11
Acquisition Time (min)
Large Scale Bioconjugation:
HNNH
s TRIS buffer S 1SH (pH 7.5, 0.1 M),
.H H20
+ OH.PCY 2  - HNSN mnr
NH 2  MAC NH H quench with
NaOS Br 3-thiopropionic acid H2N unprotected peptP3: NH2-TDEYCKSR-C(O)NH2 N0SNH,
Exact Mass: 999.44 OA-21 Exact Mass: 1316.56
10 pM 20 tM P3-1
Into a 250 mL round bottomed flask equipped with a magnetic stir bar, 8.0 mg of peptide P3 was
dissolved in water (20 mM) and Tris buffer (0.1 M, pH 7.5). A solution of the Pd reagent (OA-
21) reagent in water (40 mM) was added to the peptide solution and allowed to stir. Final
conditions: [OA-21] = 20 mM; [P3] = 10 mM; After 5 min at rt, 3-mercaptopropionic acid (3
equiv to the palladium complex, solution in 1 mL of H2 0) was added to the reaction mixture to
quench the remaining palladium species. The reaction mixture was allowed to stand for 5 min
and subsequently purified via mass-directed preparative HP-LC yielding 8.54 mg of pure
biotinylated peptide (P3-1, >99% conversion, 81% isolated yield).
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[M+3H3+ P31 Pd-species
439.86 P3-i decomposition43+8 Product by-products
Crude Reaction Mixture [M+2Hbr
659.29
46o 6o-0 ~
i 6 lb 111 2 3 4 5 6 7 8 9 10 11
3+[M+3H] P3-1
439.86 Product
Purified peptide [M+2HF
659.28
11 P I- 1460 60
General Macrocyclization Procedure
SH HS 0.1 M Tris (pH 7.5) -
MeO PCy2 H2O
+ M ,Vrt, 10 min
Sthe unprotected peptide
NaO3S H S -*C2H
-J2
10 [M 20 tM
P2: NH 2-ACYKRSDFTCGGGS-C(O)NH 2  OA-Y P2-Y
A solution of the Pd reagent (OA-Y) reagent in water (40 mM) was added to a solution of
peptide (20 mM) in Tris buffer (0.1 M, pH 7.5). Note: if the palladium reagent was not readily
soluble in H2 0, the slurry was sonicated for 10 s to facilitate this process. Final reaction
concentrations: [Pd] = 20 mM; [peptide] = 10 mM; After 10 min stirring at rt, 3-
mercaptopropionic acid (3 equiv to the palladium complex, solution in 6 mL of H20) was added
to the reaction mixture to quench the remaining palladium species. The reaction was allowed to
stand for 5 min. The crude peptide was purified using preparative HPLC as described above or
immediately analysed by LC-MS (below).
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Figure S-1: Macrocyclization P2-7
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Figure S-2: Macrocyclization P2-8
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Figure S-3: Macrocyclization P2-9
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Figure S-4: Macrocyclization P2-9 with 15% MeCN
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525.53 decomposition
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Figure S-5: Macrocyclization P2-10 with 15% MeCN
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Figure S-6: Macrocyclization P2-11
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Figure S-7: Macrocyclization P2-12
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Figure S-8: Macrocyclization P2-13
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Figure S-9: Macrocyclization P2-14
3+[M+3H]
528.90
2+[M+2H+
792.83
600 800
Pd-species
decomposition
by-products
P2-14
1 2 3 4 5 6 7 8 9 10 11
Pd-species
decomposition
Pd-specie
Control reaction by-products
without peptide
Acquisition Time (min)
Figure S-10: Macrocyclization P2-15
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Figure S-11: Macrocyclization P2-16
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Figure S-12: Macrocyclization P2-17
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Figure S-13: Macrocyclization P2-18
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Figure S-14: Macrocyclization P2-19 with 15% MeCN
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Protein Expression and Purification
pET-SUMO-DARPin plasmids were constructed as reported previously.3 Cysteine mutations
were introduced by site-directed mutagenesis using QuickChange Lightning Single Site-directed
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Mutagenesis Kit (Agilent) following manufacturer's instructions. Sequences of generated protein
constructs are summarized in Table S6.
E coli BL21(DE3) cells transformed with pET-SUMO-Protein plasmid were grown in 1
L of LB medium containing kanamycin (30 ptg/mL) at 37 'C until OD600 = 0.6. Then,
expression was induced by the addition of 0.5 mM IPTG overnight at 30 'C. After harvesting the
cells by centrifugation (6,000 rpm for 10 min), the cell pellet was lysed by sonication in 25 mL
of 50 mM Tris and 150 mM NaCl (pH 7.5) buffer containing 15 mg lysozyme (Calbiochem), 1
mg DNase I (Sigma-Aldrich), and 0.5 tablet of protease inhibitor cocktail (Roche Diagnostics,
Germany). The resulting suspension was centrifuged at 17,000 rpm for 30 min to remove cell
debris. The supernatant was loaded onto a 5 mL HisTrap FF crude Ni-NTA column (GE
Healthcare, UK), first washed with 40 mL of 20 mM Tris and 150 mM NaCl (pH 8.5), and then
washed with 40 mL of 40 mM imidazole in 20 mM Tris and 150 mM NaCl (pH 8.5). The protein
was eluted from the column with buffer containing 500 mM imidazole in 20 mM Tris and 150
mM NaCl (pH 8.5). Imidazole was removed from protein using a HiPrep 26/10 Desalting
column (GE Healthcare, UK), the protein was eluted into 20 mM Tris and 150 mM NaCl (pH
7.5) buffer. The protein was analyzed by LC-MS to confirm its purity and molecular weight.
SUMO group on SUMO-Protein was cleaved by incubating 1 pg of SUMO protease per mg of
protein at room temperature for 60 min. The crude reaction mixture was loaded onto a 5 mL
HisTrap FF crude Ni-NTA column (GE Healthcare, UK) and the flow through containing the
desired protein was collected. The protein was analyzed by LC-MS confirming sample purity
and molecular weight. Purified proteins were concentrated using Amicon 3K concentrator (50
mL, EMD Millipore); protein aliquots were flash frozen and stored in -80 'C freezer.
Protein Labelinz Experiments
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Me
SH 20 mM TRIS S
0Me PCY 2 150 mM NaCI IDA RPin) + MeO - - Me p
Me pH 7.5 DA I
NaOSC H 2030 min, rt
1[pM 10 M
DARPin Protein OA-3 Yieldb: 99%
Exact Mass: 13747.3 Da Exact Mass: 13837.53 Da
To a solution of protein (500 pmoles) in 475 pL of 20 mM Tris and 150 mM NaCi buffer (pH
7.5) was added palladium-tolyl complex OA-3 (25 pL, 200 pM) in water. The solution was
pipetted in and out of the pipette (10x) to ensure proper reagent mixing. The reaction mixture
was left at room temperature for 30 min. After this time, the reaction was quenched by the
addition of 3-thiopropionic acid (25 pL, 2 mM) dissolved in 20 mM Tris and 150 mM NaCl
buffer (pH 7.5). After an additional 5 min at rt, 500 pL of 1 : 1 CH3CN/H20 (v/v) containing
0.2% TFA was added and the resulting mixture was analyzed by LC-MS.
x1O 8 +ESI TIC Scan Frag=175.OV june-4-ajr-i-35-e.d Reaction Mixture
1.1 1 2 3
0.8.r- Protein conjugate
0.6- Pd-species
decomposition
0.4- by-products
0.2-
0 I
0.5 1 1.5 2*25 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5
Counts vs. Acquisition Time (min)
x10 6 + Scan (4.48 min) June-4-ajr-i-35-e.d Deconvoluted (Isotope Width=7.3)
Deconvoluted Spectrum of Major Peak
6
5 13837.82
428 641.8
4
3
2 13746.82
1 936873.4
13700 13750 13800 13850 13900 13950 14000
Counts vs. Deconvoluted Mass (amu)
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Table S2. DARPin-Cys protein sequence and calculated mass
Sequencea Calculated mass
GGCGGSDLGKKLLEAARAGQDDEVRILMANGADVN
AYDDNGVTPLHLAAFLGHLEIVEVLLKYGADVNAAD
13747.3 Da
SWGTTPLHLAATWGHLEIVEVLLKHGADVNAQDKF
GKTAF DISIDNGNEDLAEILQKLN
aCysteine residues highlighted in red.
ICP-MS Analysis
Two distinct macrocyclic peptides, chosen at random (P2-10 and P2-14), were dissolved in 0.4
mL of concentrated nitric acid. This solution was sonicated and diluted with MilliQ pure water to
0.2% nitric acid concentration. ICP-MS was performed on the resulting mixtures. Calibration
curves were generated using Pd ICP-MS standards for a range between 1000 ppm and 100 ppb.
There was no palladium found to be remaining in the peptide after purification. Initial palladium
content was ~300 ppm used to perform the macrocyclization reactions indicating over 99%
palladium removal.
LC-MS Characterization of Oxidative Addition Complexes
Each Pd reagent (OA-Y) reagent was dissolved in a 50:50 mixture of water:acetonitrile with
0.1% TFA and injected directly into the LC-MS and analysed via Method A in order to confirm
purity of starting materials. Due to the complexity of the NMR spectra for each oxidative
addition complex, we felt it was necessary to supply an additional measure of characterization of
each complex.
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Figure S-15: LC-MS Chromatogram of pure OA-3
0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5
Counts vs. Acquisition Time (min)
Figure S-16: LC-MS Chromatogram of pure OA-7
0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5
Counts vs. Acquisition Time (min)
Figure S-17: LC-MS Chromatogram of pure OA-8
0 .5 1 1.5 2'25 3'35 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5
Counts vs. Acquisition Time (min)
Figure S-18: LC-MS Chromatogram of pure OA-9
0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5
Counts vs. Acquisition Time (min)
Figure S-19: LC-MS Chromatogram of pure OA-10
0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5
Counts vs. Acquisition Time (min)
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Figure S-20: LC-MS Chromatogram of pure OA-1 1
0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5
Counts vs. Acquisition Time (min)
Figure S-21: LC-MS Chromatogram of pure OA-12
0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5
Counts vs. Acquisition Time (min)
Figure S-22: LC-MS Chromatogram of pure OA-13
0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5
Counts vs. Acquisition Time (min)
Figure S-23: LC-MS Chromatogram of pure OA-14
Counts vs. Acquisition Time (min)
Figure S-24: LC-MS Chromatogram of pure OA- 15
0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5
Counts vs. Acquisition Time (min)
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Figure S-25: LC-MS Chromatogram of pure OA-16
0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5
Counts vs. Acquisition Time (min)
Figure S-26: LC-MS Chromatogram of pure OA- 17
0.5 15 2 25 3 35 4 4.5 5 5.5 6 6.5 7 75 8 8.5
Counts vs. Acquisition Time (min)
Figure S-27: LC-MS Chromatogram of pure OA- 18
0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5
Counts vs. Acquisition Time (min)
Figure S-28: LC-MS Chromatogram of pure OA-19
0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5
Counts vs. Acquisition Time (min)
Figure S-29: LC-MS Chromatogram of pure OA-20
0.5 1 1.5 2 2..5 3 3 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5
Counts vs. Acquisition Time (min)
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Figure S-30: LC-MS Chromatogram of pure OA-21
0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5
Counts vs. Acquisition Time (min)
Figure S-31: LC-MS Chromatogram of pure OA-22
0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5
Counts vs. Acquisition Time (min)
Figure S-32: LC-MS Chromatogram of pure OA-23
0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5
Counts vs. Acquisition Time (min)
Figure S-33: LC-MS Chromatogram of pure OA-24
0.5 1.5 2.5 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5
Counts vs. Acquisition Time (min)
Figure S-34: LC-MS Chromatogram of pure OA-25
0.5 1.5 2.5 3 o3.5 4 4.5 k 5.5 6 6.5 7 7.5 8 8.5
Counts vs. Acquisition Time (min)
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Chapter 3. Palladium-Peptide Oxidative Addition Complexes for Bioconjugation
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3.1 - Introduction:
Reactions that modify complex biomolecules enable researchers to synthesize
molecularly defined conjugates, probe structure-function relationships, and develop new
therapeutics. 1,2 In particular, direct chemoselective bioconjugation methods are desirable
because their ability to target specific functional groups in the presence of many others
obviates the need for protecting groups or extraneous synthetic manipulations during the
synthesis of large biomolecules. 3 Bioconjugation reactions must also satisfy a number of
strict criteria to be considered practical: the reaction should be effective at low
concentrations, proceed in aqueous solutions, generate kinetically stable linkages, and
produce, at most, minor side products. 4'5 In particular, ligations between two large
biomolecules are typically conducted at low micromolar concentrations, therefore,
bioconjugation reactions must have kinetic rate constants large enough to achieve near-
quantitative conversions on experimental timescales.6
Unfortunately, many of the widely used bioconjugation reactions are still lacking in
one or more of these regards."' 7 For instance, thiol-maleimide conjugation reactions,
8
while effective, are known to generate chemically unstable linkages. Moreover, even
relatively fast reactions such as Staudinger reactions,9 oxime ligations,10 and copper-
catalyzed azide-alkyne cycloadditions," generally fail to be effective at low micromolar
6
concentrations. One noteworthy approach, which achieves the exceedingly high rates
required, is the pericylic reaction between tetrazines and strained alkenes (e.g., trans-
cyclooctenes). While impressive, the performance of the reaction is highly dependent on
the nature of the tetrazine component.1
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Figure 5: Strategies for bioconjugation mediated by palladium oxidative addition
complexes. (A) Previous reports of cysteine S-arylation with palladium-small molecule
oxidative addition complexes.' 3 (B) This report of peptide bioconjugation achieved through the
generation of palladium-peptide oxidative addition complexes.
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Recently, transition metal-mediated transformations have emerged as effective tools
in bioconjugation.' 4-' 7 Transition metals are widely used in organic synthesis for highly
selective and efficient transformations. Drawing from extensive research in this context,
we have been able to develop bioconjugation reactions that occur rapidly, exhibit
excellent chemoselectivity and proceed under the mild conditions necessary for use on
biomolecules.' 8  Recently, our laboratories reported palladium oxidative addition
complexes that rapidly and chemoselectively modify cysteine, 3 a naturally occurring
amino acid (Figure IA). With appropriate ligand modifications, this reaction was found to
take place under fully aqueous conditions while maintaining exclusive selectivity for
reaction with cysteine over other nucleophilic amino acids such as lysine.19
As an alternative to small molecule-bearing palladium reagents that functionalize
nucleophilic peptides, a complementary approach was envisioned wherein a peptide-
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bound palladium reagent could engage a diverse array of external nucleophiles (Figure
IB). We reasoned that reversing the roles of the components would enable a peptide to be
conjugated to a wide array of partners, including small molecules, peptides, or proteins,
via the synthesis of a single palladium-peptide complex.
3.2 - Results and Discussion:
To synthesize a palladium-peptide reagent, we first incorporated 4-
bromophenylalanine into the primary sequence of a peptide during solid-phase peptide
synthesis. Next, the purified unprotected peptide was treated with a water-soluble ligand
(sSPhos) and (1,5-COD)Pd(CH 2TMS) 2 in dimethylsulfoxide (DMSO) (Figure 2A).
Surprisingly, our first attempt afforded the corresponding palladium-peptide oxidative
addition complex in good yield. Moreover, the synthesis did not require specialized air-
free Schlenk techniques or the use of an inert-atmosphere glovebox. The reagents are all
commercially available and easily handled on the bench. Additional experiments revealed
that the reaction could proceed using peptides containing 4-iodophenylalanine and 4-
chlorophenylalanine.
The resulting palladium oxidative addition complexes are exceptionally stable. When
left under ambient conditions, they do not degrade for up to 12 months (Figure 2D,
Experimental). The complexes can be purified via reverse-phase high-performance liquid
chromatography (RP-HPLC) using water/acetronitrile mobile phases containing 0.1%
(v/v) trifluoroacetic acid. Regardless of the position of the 4-halophenylalanine in the
peptide, the palladium-peptide complexes can be prepared efficiently (Figure 2C). Most
importantly, the presence of other nucleophilic or basic residues (except cysteine) do not
hinder the oxidative addition process.
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Figure 6: Synthesis and characterization of palladium-peptide oxidative addition
complexes is facile and robust. (A) General procedure for the generation of
palladium-peptide complexes. (B) Palladium-peptide complex formation is efficient for
a variety of peptides containing 4-halophenylalanines. (C) Palladium-peptide oxidative
addition complexes are successfully synthesized regardless of the position of the 4-
halophenylalanine along the peptide backbone. (D) LC-MS analysis of palladium-peptide
oxidative addition complex 1B.
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Initially, we sought to apply these complexes toward late-stage side-chain
functionalization, a potentially powerful strategy for the rapid modification of unprotected
peptides. To evaluate the feasibility of this method, the oxidative addition complex, 1B,
was mixed with 5.0 equivalents of a small-molecule thiol in low micromolar
concentration in aqueous tris(hydroxymethyl)aminomethane (TRIS, pH 7.5) buffer at 37
'C. After only 30 min, we observed the expected site-selective modification of the aryl
side-chain in excellent conversions using 9 distinct thiols (Scheme 1). Moreover, the
reactivity was maintained across a wide range of aqueous buffered conditions (pH 5.5-
9.0, see Experimental for details).
Scheme 1: Palladium-peptide reagents react efficiently with small molecule thiolsa.
aYields determined by LC-MS analysis of the crude mixture as an average of two runs,
see SI for details.
. Me PC2 H20, TRIS (pH 7.5) R
MeO R-SH 37*C,1h
NaO 3S H2N KYRSEH, C(O)NH2 3-thiopropionic H2N KYRSEHO C(O)NH2
acid
10piM 50 pM
R =[- CF3  R = I.j B(OH) 2  R = 0jo R = MMe
99% 98% 99% 99%
Me F
R= M NH H R NH2  OH R = R =[
0[ OH
99% 99% 98% 98% 98%
In addition to ligation with small molecules, we envisioned that these palladium-
peptide complexes might be useful in ligation with other peptides. Peptide-peptide
conjugates are important both for studying the function of biomolecules and developing
new biotherapies for disease treatment. 20 Among others, leading chemical methods for
peptide ligation include native chemical ligation, 2 1 enzyme-mediated ligation,2 2 and
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protein-templated ligation. However, efficient conjugation of two large biomolecules
remains an outstanding challenge, with many ligation reactions requiring organic co-
solvents or failing at low micromolar concentrations. We reasoned that our palladium-
peptide reagents might allow for rapid, irreversible ligation with a variety of cysteine-
containing peptides. While the resulting linkages will not be native to proteins that occur
in nature, proteins have been shown to retain their function even with the introduction of
non-native backbones.
Using automated flow-based peptide synthesis,2 5 three peptides (P1, P2, and P3)
were prepared containing a single cysteine residue at different locations along the primary
amino acid sequence. The peptides were dissolved independently in aqueous TRIS (pH
7.5) buffer containing oxidative addition complex 1D. After 6 h at 37 'C, 3-thiopropionic
acid was added to the mixture to quench the reaction. Analysis of the reaction mixtures by
LC-MS indicated that all of the peptide ligations proceeded with both high conversions
and selectivity under these conditions (Scheme 2).
Given these results, we envisioned that another class of suitable nucleophiles
would be cysteine-containing proteins. This kind of peptide-protein conjugation could
potentially allow site-specific attachment of therapeutic peptides to antibodies or other
large proteins containing cysteine, a strategy of significant interest for the development of
262targeted therapeutics or vaccines.26,27 Furthermore, the ability to generate bioconjugates
of natural proteins under physiologically relevant conditions in dilute aqueous solutions
would be a unique application of metal-mediated cross coupling. An additional advantage
of this method is that the aryl thioether bond is known to exhibit high chemical stability. 3
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Scheme 2: Palladium-peptide reagent enables peptide-peptide ligation. (A) Peptide
ligation with internal cysteine, (B) Peptide ligation with cysteine near N-terminus, and
(C) Peptide ligation with cysteine near C-terminusa
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As a model substrate, the protein Protective Antigen (PA) 2 8,2 9 from Bacillis
anthacis was modified to contain a single internal cysteine (see Experimental for details).
In aqueous buffer containing TRIS (pH 7.5) and sodium chloride, PA (1 11 M) was
incubated with 5 equivalents of palladium-peptide complex 1B. After only 1 hour at 37
OC, quantitative conjugation of the peptide to the protein was observed (Scheme 3).
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Scheme 3: Ligation of a peptide to anthrax toxin Protective Antigen proceeds in one
hour at low micromolar concentrations. aYield determined by deconvolution of mass
spectrum.
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3.3 - Conclusion:
In conclusion, palladium-peptide oxidative addition complexes were synthesized through the
introduction of 4-halophenylalanine into peptides during SPPS. These complexes react
efficiently with small molecule thiols, as well as cysteine-containing peptides and proteins. The
ligation reactions proceed at low concentrations under physiologically relevant conditions. These
transformations represent a new bioconjugation approach, complementary to current methods.
We anticipate applications in the development of targeted therapeutics, the investigation of
structure-function relationships, and the design of unconventional, branched polypeptide
structures.
3.4 - Experimental:
General Reagent Information
1 -[Bis(dimethylamino)methylene]- 1 H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide
hexafluorophosphate (HATU), Fmoc-L-Gly-OH, Fmoc-L-Leu-OH, Fmoc-L-Ile-OH, Fmoc-L-
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Lys(Boc)-OH, Fmoc-L-Ala-OH, Fmoc-L-Cys(Trt)-OH, Fmoc-L-Gln(Trt)-OH, Fmoc-L-
Asn(Trt)-OH, Fmoc-L-Glu(OtBu)-OH, Fmoc-L-Asp-OH, Fmoc-L-Arg(Pbf)-OH, Fmoc-L-Phe-
OH, Fmoc-L-Ser(tBu)-OH, Fmoc-L-Trp-OH, Fmoc-L-Thr(tBu)-OH, Fmoc-L-Tyr(tBu)-OH, and
Fmoc-L-His(Trt)-OH were purchased from CreoSalus, Inc (Louisville, KY). Fmoc-4-iodo-L-
phenylalanine, Fmoc-4-bromo-L-phenylalanine, and Fmoc-4-chloro-L-phenylalanine were
purchased from Chem-Impex International (Wood Dale, IL). H-Rink Amide-ChemMatrix resin
was obtained from PCAS BioMatrix Inc. (St-Jean-sur-Richelieu, Quebec, Canada). PyAOP was
purchased from P3 BioSystems (Louisville, KY). Peptide synthesis-grade NN-
dimethylformamide (DMF), dichloromethane (CH2Cl 2), diethyl ether, and HPLC-grade
acetonitrile were obtained from VWR International (Philadelphia, PA). Small molecule thiols
were purchased from Aldrich Chemical Co., Alfa Aesar, or Matrix Scientific and were used
without additional purification. All deuterated solvents were purchased from Cambridge Isotopes
and used without further purification. All other reagents were purchased from Sigma-Aldrich and
used as received.
All reactions with peptides were set up on the bench top and carried out under ambient
conditions. Dimethylsulfoxide (DMSO), pentane, and cyclohexane were purchased from Aldrich
Chemical Company in SureSealiM bottles and were purged with argon before use. The ligand
used during this study, sSPhos, was generously gifted from Aldrich Chemical Company.
All small-molecule organic and organometallic compounds were characterized by 'H, 3 C
NMR, and IR spectroscopy, as well as high-resolution mass spectrometry (unless otherwise
noted). 3 1P NMR spectroscopy was used for characterization of palladium complexes. Copies of
the 'H, 13C, and 3 1P NMR spectra can be found at the end of the Supporting Information. Nuclear
Magnetic Resonance spectra were recorded on a Bruker 400 MHz instrument and a Varian 300
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MHz instrument. Unless otherwise stated, all 'H NMR experiments are reported in 6 units, parts
per million (ppm), and were measured relative to the signals of the residual proton resonances
methanol-d 4 (4.78 and 3.31 ppm) in the deuterated solvents. High resolution mass spectra were
obtained on a Bruker Daltonics APEXIV 4.7 Tesla Fourier transform ion cyclotron resonance
mass spectrometer (FT-ICR-MS). Matrix assisted laser desorption/ionization time of flight mass
spectrometry (MALDI-TOF-MS) analysis was performed on a Bruker MicroFlex using positive
reflector mode.
LC-MS chromatograms and associated mass spectra were acquired using Agilent 6520
ESI-Q-TOF mass spectrometer. Solvent compositions used in the LC-MS are 0.1% formic acid
in H20 (solvent A) and 0.1% formic acid in acetonitrile (solvent B). The following LC-MS
method was used:
Method A LC conditions: Zorbax 300SB C3 column: 2.1 x 150 mm, 5 pm, column temperature:
40 'C, gradient: 0-2 min 1% B, 2-11 min 1-61% B, flow rate: 0.8 mL/min. MS conditions:
positive electrospray ionization (ESI) extended dynamic mode in mass range 300 - 3000 m/z,
temperature of drying gas = 350 'C, flow rate of drying gas = 11 L/min, pressure of nebulizer
gas = 60 psi, the capillary, fragmentor, and octapole rf voltages were set at 4000, 175, and 750,
respectively.
Determination of Bioconjugation Conversions
Data were processed using Agilent MassHunter software package. All reported yields
were determined by integrating total ion current (TIC) spectra. First, the peak areas for all
relevant peptide-containing species on the chromatogram were integrated using Agilent
MassHunter software package. Since no peptide-based side products were generated in the
experiments, the yields shown in Schemes 1, 2, and 3 were determined as follows: %yield =
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Spr/Stotai where Spr is the peak area of the product and Stotai is the peak area of combined peptide-
containing species (product and starting material). For protein bioconjugation, deconvoluted
masses of proteins were obtained using maximum entropy algorithm. LC-MS data shown were
acquired using Method A, unless otherwise noted. Mass spectrum insets correspond to the
integration of the TIC peak unless otherwise noted. In order to provide clarity, an example of
how bioconjugation conversion is detailed below:
OMe PGy2 H20, TRIS (pH 7.5)MeO + SH 37 C, 1 h
I / BrKY-RSH the
NaO3S KYRSEH 3-thioproplonic H 2N KY C(O)NH 2
acid
10 sM 50 [M exact mass: 1533.70
The crude reaction mixture is depicted below:
product
starting
material
1 2 3 4 5 6 7 8 9 10 11
Counts vs. Acquisition Time (min)
This mixture was analyzed by LC-MS using Agilent MassHunter software package. The peptide-
containing peaks that correspond to the starting material and product were identified by mass as
can be seen from the inlets depicted below.
186
3+
3+ 512.23
[M+3H]
464.85 product M2+
[M+2H + 767.85
696.761
[M -4q-L starting L 400 600 800
400 660 860 ma~teial
4 7 8 9 10 11
Counts vs. Acquisition Time (min)
Finally, using the calculation described above, the Agilent MassHunter software package was
used to integrate below the starting material and product peaks to determine the percent of
conversion to the product.
98%
119965566.81
2%
2607542.13
1 2 3 4 5 6 7 8 9 10 11
Counts vs. Acquisition Time (min)
In some cases, a small non-peptidic impurity near the starting material was found, resulting in an
additional peak. This peak was omitted from conversion calculations because it does not
correspond to total peptide-containing species.
Linear Peptide Synthesis
All peptides were synthesized on a 0.2 mmol scale using automated Fmoc-SPPS chemistry under
flow as previously described.2 Specifically, ChemMatrix Rink Amide HYR resin (200 mg) was
loaded into a reactor maintained at 90 *C. All reagents were flowed at 80 mL/min with HPLC
pumps through a stainless-steel loop maintained at 90 *C before introduction into the reactor. For
each coupling, 10 mL of a solution containing 0.2 M amino acid and 0.17 M HATU in DMF
were mixed with diisopropylethylamine (200 gL) and delivered to the reactor. Fmoc removal
was accomplished using 20% (v/v) piperidine (10.4 mL). Between each step, DMF (15 mL) was
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used to wash out the reactor. Special coupling conditions were used for arginine, in which the
flow rate was reduced to 40 mL/min and 10 mL of a solution containing 0.2 M Fmoc-L-
Arg(Pbf)-OH and 0.17 M PyAOP in DMF were mixed with diisopropylethylamine (200 piL) and
delivered to the reactor.
After completion of the stepwise, automated SPPS, the resin was washed thoroughly with
CH2Cl 2 and dried under vacuum. The peptide was simultaneously cleaved from the resin and the
side-chains were deprotected by treatment with 5mL of the cleavage cocktail containing 82.5%
TFA, 5% phenol, 5% thioanisole, 5% water, and 2.5% EDT (v/v) at 60 'C for 8 min. The
resulting solution was then triturated and washed with cold diethyl ether (3x). The obtained solid
was dissolved in a solution of 50% H20 and 50% acetonitrile containing 0.1% TFA and
lyophilized. The following peptides were synthesized following this procedure:
HN NH2
NH
NH2 
N NH2
HHO H> H OH 0_ 0 
-COH 
0 0OH
NH 2
P1
Thr Phe Asp Tyr Cys Lys Ser Val Arg
mass: 1116.54
0
NH
N N N, , H H N N H
H N O 0
HN 0 NH2
H 2N NH
P2
Phe Cys Trp Arg Ala lie Asp Ser Thr Gin Gly Val
mass: 1380.66
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NH2  H2N NH
HN 0 OH
O H 0  SH
~J2 ~ N  y N O R ~ O( HOj'NH N N- NH
NH, H H 0 H 0 %, NH0
P3
Phe Lys Trp Arg lie Asp Ser Thr Gin Glu Val Cys Ala
mass: 1580.78
NH2  H 2N NH
HN 0 OH 0 NH 2
-' HH H H H
N N N N NH2H H H H
NQaOH
P4
4-iodoPhe Ala Lys Tyr Arg Ser Glu His Gin Trp
mass: 1475.56
NH2  H 2N yNH
HN 0 OH 0 NH2
Br
- NHH 0 H 0 H 0 H
Br.N N .. N N N HNH2
0 N, OH 0 Nf^NHO 6NH
OH N
p5
4-bromoPhe Ala Lys Tyr Arg Ser Glu His Gin Trp
mass: 1427.52
NH2  H 2N NH
HN OH 0 NH 2
C0N N N N z IkN H20 OH X HH
0 - O OH NH O NHO NH
PI
4-chloroPhe Ala Lys Tyr Arg Ser Giu His Gin Trp
mass: 1383.62
189
NH2  NH2
N N N H N N ANH2
NH2
lie Thr Phe Gin Asp Lou LoAsp 2Ty2 TyrGly Lys Lys Lys 4-lodoPhe
NH2 H2N NH
N N N
N~N~~ ~HOH H HH
NH2 H - H H 0
H 0 OHNH 2
Ps
Ala Lys Lyr Arg 4b r Tyo r 14 Glu His Gin Trp
mass: 2.1
Peptide Purification
Peptides were dissolved in water and acetonitrile containing 0.1% TFA, filtered through a 0.22
pm nylon filter and purified by mass-directed semi-preparative reversed-phase HPLC (RP-
HPLC). Solvent A was water with 0. 1% TFA additive and Solvent B was acetonitrile with 0. 1%
TFA additive. A linear gradient from 5-45% B changing a rate of 0.5% B/min was used. The
peptides were purified on an Agilent Zorbax SB C3 column: 9.4 x 250 mm, 5 ptm. Using the
mass data collected for each fraction from the instrument, only pure fractions were combined and
Iyophilized. The purity of the fraction pool was confirmed by LC-MS. Total-ion current
chromatograms for each peptide is shown below.
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Synthesis of Pd-Peptide Oxidative Addition Complexes
Synthesis of [(1,5-COD)Pd(CH 2TMS)2]. This compound was synthesized according to the
procedure reported in the literature.' The 'H and "C NMR spectra of the obtained material are
identical to those reported in the literature.' The title compound was stored in a freezer at -20 'C.
General Procedure for the Synthesis of Palladium-Peptide Oxidative Addition Complexes.
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sSPhos (2.5 equiv)
g~::: ' TMS
Cetide ) rt,1 h tid
Na3Sa / __qpgide
1.0 equiv 2.5 equiv (sSPhos)Pd(Ar)X
In a scintillation vial (10 mL) open to the air and equipped with a magnetic stir bar, the vial was
charged with sSPhos ligand (2.5 equiv), peptide-Ar-X (1 equiv), and DMSO (1 mL). Solid (1,5-
COD)Pd(CH 2SiMe 3)2 (2.5 equiv) was added rapidly in one portion and the resulting solution was
stirred for 1 h at rt.* After this time, the solution was frozen by placing the capped vial into a
liquid nitrogen bath and subsequently lyophilized to remove the DMSO. The Pd-Peptide
oxidative addition complexes were purified via mass-directed preparative RP-HPLC.
*The synthesis of the OA complex containing the ArCl (1C) requires 5 equiv of (1,5-
COD)Pd(CH2SiMe 3)2 to reach full conversion in 1 h.
OMe CY2MeO
NaO 3S HN 
AKYRSEHQW-C(O)NH 2
0
1A
Following the general procedure, a mixture containing peptide P4 (10 mg, 0.006 mmol), sSPhos
(8.7 mg, 0.017 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (6.5 mg, 0.017 mmol) was stirred at rt in
DMSO (1.5 mL) for 1 h. General work-up afforded 1A as a white solid (7.60 mg, 65%).
HRMS electrospray (m/z): [M - NaI]l caled for C89H120 IN 19NaO 20PPdS: 1943.75, found
1943.77.
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OMe PCY2MeO~J1
Br OAKYRSEHQW-C(O)NH 2
N803S BrH 2N 02
1B
Following the general procedure, a mixture containing peptide P5 (10 mg, 0.006 mmol), sSPhos
(8.7 mg, 0.017 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (6.5 mg, 0.017 mmol) was stirred at rt in
DMSO (1.5 mL) for 1 h. General work-up afforded lB as a white solid (5.60 mg, 48%).
HRMS electrospray (m/z): [M - NaBr calcd for C8,H 120BrN1,NaO 2OPPdS: 1943.75, found
1943.77.
OMe PCY2MeO
NaO 3 S H 2N 
AKYRSEHQW-C(O)NH 2
0
1C
Following the general procedure, a mixture containing peptide P6 (10 mg, 0.006 mmol), sSPhos
(8.7 mg, 0.017 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (13 mg, 0.034 mmol) was stirred at rt in
DMSO (1.5 mL) for 1 h. General work-up afforded 1C as a white solid (1.60 mg, 33%).
HRMS electrospray (m/z): [M - NaCIj caled for C89H120CN 1NaO 20PPdS: 1943.75, found
1943.76.
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0H2N- ITFQDLLDYYGKKKA
SO3Na
OMe
MteOC
N C(O)NH 2 Cy2P M
H
1D
Following the general procedure, a mixture containing peptide P7 (10 mg, 0.0038 mmol),
sSPhos (4.8 mg, 0.0095 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (3.7 mg, 0.0095 mmol) was stirred
at rt in DMSO (1.5 mL) for 1 h. General work-up afforded 1D as a white solid (7.72 mg, 77%).
HRMS electrospray (m/z): [M - NaI]l calcd for C117H169IN 20NaO28PPdS: 2620.99, found
2621.00.
H
N
H2N-AKYR'
0
i .SEHQW-C(O)NH 2
SBr SO3Na
--T OMe
Cy2P MeO
1E
Following the general procedure, a mixture containing peptide P8 (10 mg, 0.006 mmol), sSPhos
(8.7 mg, 0.017 mmol), and (1,5-COD)Pd(CH 2TMS) 2 (6.5 mg, 0.017 mmol) was stirred at rt in
DMSO (1.5 mL) for 1 h. General work-up afforded 1E as a white solid (3.80 mg, 33%).
HRMS electrospray (m/z): [M - NaBr+ caled for C91H122N 1902 1PPdS: 1943.75, found
1943.74.
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Palladium-Peptide Oxidative Addition Complex Purification
Although the purified palladium-peptide oxidative addition complexes are readily soluble
in aqueous solutions, we found that the crude palladium-peptide oxidative complexes exhibited
limited solubility, likely due to the excess ligand. Therefore, after lyophization, the palladium-
peptide oxidative addition complexes were dissolved in 2 mL of a 50:50 (v/v) mix of water and
acetonitrile containing 0.1% TFA. The solution was diluted with 1 mL of water containing 0.1%
TFA, filtered through a 0.22 pim nylon filter, and purified by mass-directed semi-preparative
reversed-phase HPLC (RP-HPLC). Solvent A was water with 0.1% TFA additive and Solvent B
was acetonitrile with 0.1% TFA additive. A linear gradient from 15-50% B changing at a rate of
0.5% B/min was used. The peptides were purified on an Agilent Zorbax SB C3 column: 9.4 x
250 mm, 5 pm.
Using mass data from the instrument about each fraction, pure fractions were pooled and
lyophilized. Despite different retention times, peptide OA complexes and ligand often co-elute,
which can reduce overall yield (particularly for 1C). The purity of the fraction pool was
confirmed by LC-MS. Total-ion current chromatograms for each complex is shown below. With
electrospray ionization, we observe ions corresponding to each palladium-peptide oxidative
addition complex without sodium and halide. An additional characterization of OA complex 1B
using MALDI-TOF-MS is also presented, and we also observe the loss of sodium and halide.
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The LC-MS chromatogram of OA complex 1A has a peak at 8.4 min that corresponds to free
ligand. HPLC purification fails to fully resolve the complex from the ligand, and techniques to
improve the purification have been unsuccessful but the subsequent reactivity of the complex is
identical to that of the other Pd-peptide complexes.
IB:
3+
[M-NaBr]
648.92
2+
[M-NaBr]
972.88
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Acquisition Time (min)
AL
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3+
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1C:
ID:
3+ 2+[M-Nal] [M-NaI]
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1E:
3+[M-NaBr]
648.93
[M-NaBr]
972.89
600 800 100
1 2 3 4 5 6 7 8 9 10 11
Acquisition Time (min)
For the LC-MS chromatogram of OA complex 1E, there are two peaks at 8 min. These peaks are
isobaric, and presumably arise due to two distinct confirmations of the ligand when the
bromophenylalanine is in the middle of the peptide (i.e. rotomers).
MALDI-TOF-MS Analysis
For purified OA complex 1B, the compound was also analyzed using MALDI-TOF-MS. Shown
below is the spectrum obtained after preparing the sample in a-cyano-4-hydroxycinnamic acid
matrix. The spectrum was acquired in positive reflector mode, with PIE delay set to 240 ns, laser
repetition rate set to 60 Hz, reflector detector voltage set to 1.854 kV, ion source voltage 1 set to
19 kV, ion source voltage 2 set to 15.9 kV, ion source lens voltage set to 9.1 kV, and the number
of shots set to 400. Mass expected [M -Na, -Br, +H]: 1943.7. Mass observed: 1944.1. The
additional peak at 1350.9 corresponds to M -Na, -Br, -Pd, -ligand, +H.
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General Bioconiuration Procedure
0MG PCY2MeO _--
NaO3S -
H 20, TRIS (pH 7.5)
+ R-SH 37-C,1h
then
3-thioproplonic
acid
' R
H 2N C(O)NH2
10pM 50pVM
A solution of the palladium-peptide reagent 1B (20 pM) in water was added to a equal
volume of a solution containing the small molecule thiol (100 iM) in 0.1 M TRIS buffer at pH
7.5. The palladium reagents were sonicated for 10 s to ensure the reagents were fully dissolved.
Final conditions: [Pd] = 10 p.M; [R-SH] = 50 pM; After 1 h at 37 *C, of 3-mercaptopropionic
acid (3 equiv) dissolved in H20 was added to the reaction mixture to quench the remaining
palladium species. The reaction was allowed to stand for 5 min and subsequently characterized
by LC-MS.
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MeO OMe P Y2
N83 Br
NaO 3S0 .AM
10 ptM
+ F3C -QSH
50 IM
H20, TRIS (pH 7.5)37 -C, 1 h
then
3-thiopropionic
acid
CF3
H2N C(O)NH 2
mass: 1525.65
Following the general bioconjugation procedure with 4-(trifluoromethyl)benzenethiol (50
uM) resulted in a 99% conversion to the desired product as determined by LC-MS analysis.
[M+3H r]uc
1523.562
784 83 starting
6 Boomaterial
3 4 5 6 7
Acquisition Time (min) 8 9 10 11
OMe PCY 2MeO J- - -
Br
NaO3S
10 pM
+ (HO)2B-QSH
50 pM
H20, TRIS (pH 7.5)37 -C, 1 h
then
3-thiopropionic
acid
B(OH)2
H2N C(O)NH 2
mass: 1501.67
Following the general bioconjugation procedure with 4-mercaptophenylboronic acid (50
uM) resulted in a 98% conversion to the desired product as determined by LC-MS analysis.
[M+501
600
3+
3H]
,.57 product
2+
[M+2H
751.86
starting
material
800
3 4 5 6 7
Acquisition Time (min)
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1 2
1 2 S i 1,0 1-1
OMe PY2MeO
Br
NaO 3S HOW
10 ptM
H2N -a SH
50 1 M
H20, TRIS (pH 7.5)
37 -C, 1 h
then
3-thioproplonic
acid
NH2
H2N -- - C(O)NH 2
mass: 1472.68
Following the general bioconjugation procedure with 4-aminothiophenol (50 uM) resulted
in a 99% conversion to the desired product as determined by LC-MS analysis.
pro Uct
starting
material
1 2 3 4 5 6 7
Acquisition Time (min) 8 9 10 11
MeO IMe 2
Br
NaO3S
10 pM
+ HO-jSH
50 pM
H20, TRIS (pH 7.5)37 -C, 1 h
then
3-thiopropionic
acid
OH
H 2N SEH C(O)NH 2
mass: 1473.67
Following the general bioconjugation procedure with 4-mercaptophenol (50 uM) resulted
in a 98% conversion to the desired product as determined by LC-MS analysis.
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3+
EM+3H]
506.03
2+
[M+2H]
758.52
600 80
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Acquisition Time (min)1
MM 02 4MeO 
i
NaOaS B
10 M
F
+ SH
50 pM
H 20, TRIS (pH 7.5)37 'C, 1 h
then
3-thioproplonic
acid
F
H2NEmassC(1)NH52
mass: 1475.66
Following the general bioconjugation procedure with 2-fluorothiophenol (50 uM) resulted
in a 98% conversion to the desired product as determined by LC-MS analysis.
M+ 
product
[M+3H]
506.89
[M+2H]
759.84 starting
6 ,0 material
600 800
3 4 5 6 7
Acquisition Time (min) 8 9 10 11
MeO OMe PY2
Br
NaO3S ?HQ
10 M
H 20, TRIS (pH 7.5)
37'C,1h
+ Q-SH then
3-thloproplonic
acid
50 IM
H2N EH C(O)NH 2
mass: 1465.69
Following the general bioconjugation procedure with 4-mercaptotetrahydropyran (50 uM)
resulted in a 99% conversion to the desired product as determined by LC-MS analysis.
3+ product
[M+3H]
503.57
[M+2H]
754.86 starting
, I ,material
660 860
2 3 4 5 6 7
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1 2
1
OM. PCY2MOO '.. /_\
NaOsS
10 pM
e Me
+ M e . ' SH
Me H
50 IM
H20, TRIS (pH 7.5)37 C, 1 h
then
3-thioproplonic
acid
M eMe
. H Me
H2N C(O)NH 2
mass: 1749.98
Following the general bioconjugation procedure with thiocholesterol (50 uM) resulted in a
99% conversion to the desired product as determined by LC-MS analysis.
[M+
584
600
3+
.33 product
3 4 5 6 7
Acquisition Time (min) 8 9 10 11
M OMe PCY 2
Br
NaO 3S EHr
10 M
+
S
-S H
50 pM
H20, TRIS (pH 7.5)37 *C, 1 h
then
3-thioproplonic
acid
N
H2N C(O)NH 2
mass: 1540.65
Following the general bioconjugation procedure with 4-phenylthiazole-2-thiol (50 uM)
resulted in a 98% conversion to the desired product as determined by LC-MS analysis.
3+[M+3H] product
[M+2H-1
771.33
starting
majterial
3 4 5 6 7
Acquisition Time (min)
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[M+2Hi
875.99
starting
material
Me Me
OINH
OMe H2  M H 0 H20, TRIS (pH 7.5) S OMeO - -+ Me OH 37 *C, I h H OH
Na3 Br SH then
NaO3S 3-thioproplonic H2N Q C(O)NH 2
acid
10 pM 50 pM mass: 1538.71
Following the general bioconjugation procedure with N-isobutyryl-D-cysteine (50 uM)
resulted in a 99% conversion to the desired product as determined by LC-MS analysis.
3+ product
[M+3H]
503.57
[M+2H]
754.86
startijng
material
600 Boo
1 2 3 4 5 6 7 8 9 10 11
Acquisition Time (min)
General pH Study Procedure - (Buffer Experiments)
OM 2 H20, buffer (pH 5.5-9.0)
MeO j. _. SH 37 *C, 1 h
N Br then
NaO3S 3-thioproplonic H2N C(O)NH2
acid
10 pM 50 IM mass: 1533.70
A solution of the palladium-peptide reagent 1B (20 pM) in water was added to a equal
volume of a solution containing biphenyl-4-thiol (100 pM) in buffer (0.1 M, Phosphate buffer =
pH 5.5-7.0, TRIS buffer = pH 7.5-9.0). The palladium reagents were sonicated for 10 s to ensure
the reagents were fully dissolved. Final conditions: [Pd] = 10 gM; [biphenyl-SH] = 50 pLM; After
1 h at 37 *C, 3-mercaptopropionic acid (3 equiv) dissolved in H20 was added to the reaction
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mixture to quench the remaining palladium species. The reaction was allowed to stand for 5 min
and subsequently characterized by LC-MS.
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General Halide Studv Procedure - (Halide Effect Experiments)
OMeH 20, TRIS (pH = 7.5)MeO - SH 37*C, 30 min
X then
NaO 3 S 3-thioproplonic H2N C(O)NH 2
acid
10 pM 50 pM mass: 1533.70
X =1, Br, CI
A solution of the palladium-peptide reagent 1A, IB, or 1C (20 pM) in water was added
to an equal volume of a solution containing biphenyl-4-thiol (100 pM) in in buffer (0.1 M TRIS
buffer = pH 7.5). The palladium reagents were sonicated for 10 s to ensure the reagents were
fully dissolved. Final conditions: [Pd] = 10 pM; [biphenyl-SH] = 50 ptM; After 1 h at 37 *C, 3-
mercaptopropionic acid (3 equiv) dissolved in H20 was added to the reaction mixture to quench
the remaining palladium species. The reaction was allowed to stand for 5 min and subsequently
characterized by LC-MS.
3+ product
526.23
X I [M+2H]X= / 788.82
starting J
600 8o0 material
4 57 1"0 11
Acquisition Time (min)
526.23 product
X=Br [M+2H]X = Br788.83
starting
600 800 material
1 2 3 4 5 6 7 8 1"0 1'1
Acquisition Time (min)
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Acquisition Time (min)
Protein Expression and Purification
pD444 PAC-CO plasmids were constructed as previously reported.3 Cysteine mutations
were introduced by site-directed mutagenesis using QuickChange Lightning Single Site-directed
Mutagenesis Kit (Agilent) following the manufacturer's instructions. Sequences of the generated
protein construct are summarized in Table 51.
PA[K653C] was expressed in the periplasm of E. coli BL21(DE3) cells. Cells were
grown in LB medium containing ampicillin (100 pg/mL) at 37 'C to an A600 of 0.8. Expression
was induced by addition of IPTG to final concentration of 0.4 mM, and the culture was grown
overnight at 18 'C. The protein was purified by anion exchange chromatography followed by
size exclusion chromatography.
The protein was analyzed by LC-MS confirming sample purity and molecular weight.
Protein aliquots were flash frozen and stored in -80 'C freezer.
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Protein Labeling Experiments
H S
MoOMO PCY2MeV .. - H2Nrli.. COOH
NaO 3S I/ Br. +
1B
5 sM
20 mM TRIS (pH 7.5)
150 mM NaCI, H2037 -C, 1 h
then
3-thloproplonlc
acid
Protective Antigen
mass: 82800 Da
1 pLM
0
H 2N Y NH2
/
H12N- protein)-COOH
mass: 84190 Da
99%8
82800.06 84190.61
pure Protective Antigen
with Cys mutation crude reaction mixture
81000 82000 83000 84600 85000 86600 87000 8000 89000 81000 82000 83000 84000 85000 88000 87000 88000 89000
Counts vs. Deconoluted Mass (amu) Counts vs. Deconvoluted Mass (amnu)
To a solution of protein (500 pmoles) in 475 pL of 20 mM Tris and 150 mM NaCl buffer
(pH 7.5) was added palladium-peptide complex 1B (25 gL, 100 gM) in water. The solution was
pipetted up and down (lOx) to ensure proper reagent mixing. The reaction mixture was left at 37
*C for 1 h. After this time, the reaction was quenched by the addition of 3-thiopropionic acid (25
pL, 2 mM) dissolved in 20 mM Tris and 150 mM NaCl buffer (pH 7.5). After an additional 5
min at rt, 500 pL of 1:1 CH3CN/H 20 (v/v) containing 0.1% TFA was added and the resulting
mixture was analyzed by LC-MS.
Crude Reaction N ixture
1 2 3 i 8 9 10 11
Counts vs. Acquisition Time (min)
Pure Protective Antigen
with Cys Mutation
3 4 s 6 7 8 9 10 11
Counts vs. Acquisition Time (min)
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Deconvoluted mass spectrum:
82800.06
pure Protective Antigen
with Cys mutation
84190.61
crude reaction mixture
81600 82000 83000 84000 85000 86000 87000 88000 88000 81000 82000 83000 84000 85000 88000 87000 800 8800Counts vs. Deconvoluted Mass (amsu) Counts vs. Deconvoluted Mass (amsu)
Table Si. Protective Antigen-Cys protein sequence and calculated mass
Sequencea Calculated mass
MEVKQENRLLNESESSSQGLLGYYFSDLNFQAPMVV
TSSTTGDLSIPSSELENIPSENQYFQSAIWSGFIKVKKS
DEYTFATSADNHVTMWVDDQEVINKASNSNKIRLEK
GRLYQIKIQYQRENPTEKGLDFKLYWTDSQNKKEVI
SSDNLQLPELKQKSSNSRKKRSTSAGPTVPDRDNDGI
PDSLEVEGYTVDVKNKRTFLSPWISNIHEKKGLTKY
KSSPEKWSTASDPYSDFEKVTGRIDKNVSPEARHPLV
AAYPIVHVDMENIILSKNEDQSTQNTDSETRTISKNTS
TSRTHTSEVHGNAEVHASFFDIGGSVSAGFSNSNSSTV
AIDHSLSLAGERTWAETMGLNTADTARLNANIRYVN 82800.04 Da
TGTAPIYNVLPTTSLVLGKNQTLATIKAKENQLSQIL
APNNYYPSKNLAPIALNAQDDFSSTPITMNYNQFLEL
EKTKQLRLDTDQVYGNIATYNFENGRVRVDTGSNW
SEVLPQIQETTARIIFNGKDLNLVERRIAAVNPSDPLE
TTKPDMTLKEALKIAFGFNEPNGNLQYQGKDITEFD
FNFDQQTSQNICNQLAELNATNIYTVLDKIKLNAKM
NILIRDKRFHYDRNNIAVGADESVVKEAHREVINSST
EGLLLNIDKDIRKILSGYIVEIEDTEGLKEVINDRYDM
LNISSLRQDGKTFIDFKKYNDKLPLYISNPNYKVNVY
AVTKENTIINPSENGDTSTNGIKKILIFSKKGYEIG
aCysteine residue highlighted in red.
Oxidative Addition Complex Stability
When stored as a solid or kept frozen in solution, the palladium-peptide oxidative addition
complexes display remarkable stability for upwards of 12 months and show no diminished
reactivity. This is confirmed via a set of experiments wherein the oxidative addition complexes
were stored as either a frozen solution or solid and then, after 12 months, allowed to react with a
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small molecule thiol. The reaction conversions are comparable to that of a freshly prepared
palladium-peptide oxidative addition complex.
H20, buffer (pH 5.5-9.0) S
MeO O- - 37'C, 1 hJJ Br - S then
NaO3S 3-thiopropionic H2N RSEHQ C(O)NH 2
acid
10 JM 50 [M mass: 1533.70
A solution of the palladium-peptide reagent 1B (20 ptM) in water was added to a equal
volume of a solution containing biphenyl-4-thiol (100 tM) in TRIS buffer (0.1 M, pH 7.5). The
palladium reagents were sonicated for 10 s to ensure the reagents were fully dissolved. Final
conditions: [Pd] = 10 pM; [biphenyl-SH] = 50 ptM; After 1 h at 37 *C, 3-mercaptopropionic acid
(3 equiv) dissolved in H20 was added to the reaction mixture to quench the remaining palladium
species. The reaction was allowed to stand for 5 min and subsequently characterized by LC-MS.
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Stability in Solution
The three palladium-peptide oxidative addition complexes (1A, 1B, and 1C) were
dissolved in 50% water / 50% acetonitrile containing 0.1% TFA at a concentration of 300
nanograms / pL. The solutions were analysed by LC-MS using method A after 1, 2, and 3 days.
For compounds 1A, 1B, and 1C, the peaks ~5.6 minutes have mass 1349.7 Da and 1374.7 Da,
which corresponds with replacement of Pd with either a proton (H+) or nitrile group (-CN). For
compound 1C, the peak -5.7 minutes corresponds to peptide P6.
Compound 1a
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Complex 1B MS/MS Characterization
To confirm that the palladium is located at the N-terminal 4-bromophenylalanine residue, and
not elsewhere on the peptide, we subjected oxidative addition complex 1B to LC-MS/MS
analysis. Method A was modified to acquire secondary MS spectra targeting specific ions. Ions
with z = +2 and m/z = 973.87 or 973.37 Da were selected for secondary MS. Shown below is the
secondary MS spectrum at 7.95 minutes for the 973.37 Da ion, with CID at 37.3.
1800
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300
300 600 900 1200 1500 1800
m/z
The data were analysed using mMass software. The presence of palladium makes comprehensive
analysis of the MS/MS data challenging due its isotopic abundance (deisotoping alogrithms do
not account for the multiple Pd isotopes). Therefore, a few selected ions are shown below.
Critically, no y-ions exhibited an isotope pattern suggestive of palladium, as would be expected
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for a palladium complex on the N-terminal residue. Additionally, the b-ions exhibited the
characteristic palladium isotope pattern.
Ion Fragment Expected Monoisotopic
Mass (z = +1)
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